株探米国株
エドガーで原本を確認する

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of July 2026

 

Commission File Number: 001-42453

 

Park Ha Biological Technology Co., Ltd.

 

901 & 902-2, Building C

Phase 2, Wuxi International Life Science Innovation Campus

196 Jinghui East Road

Xinwu District, Wuxi, Jiangsu Province

People’s Republic of China 214000

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F ☒       Form 40-F ☐

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit No.   Description
99.1   Operating and Financial Review and Prospects in Connection with the Unaudited Consolidated Financial Statements for the Six Months Ended April 30, 2026 and 2025
99.2   Unaudited Consolidated Financial Statements for the Six Months Ended April 30, 2026 and 2025
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Park Ha Biological Technology Co., Ltd.
     
Date: July 24, 2026 By: /s/ Xiaoqiu Zhang
  Name:  Xiaoqiu Zhang
  Title: Chief Executive Officer, Chairperson of the Board of Directors

 

2

 

EX-99.1 2 ea029900901ex99-1.htm OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED APRIL 30, 2026 AND 2025

Exhibit 99.1

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes that appear in this report. In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report. All amounts included herein with respect to the six months ended April 30, 2026 are derived from our consolidated financial statements included elsewhere in this report. Our financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles, or U.S. GAAP.

 

Overview

 

Our business primarily consists of developing our private skincare label, direct skincare products sales and franchise alliances promotions. Our “Park Ha” brand focuses on providing solutions for problematic skin. Established in 2016, the brand had its first store launched in 2017. In addition to the three stores directly operated by Park Ha Jiangsu, as of April 30, 2026 and 2025, we had 21 and 39 franchisees in China, of which 21 and 38 franchisees operate under the store name “Park Ha”. As of April 30, 2026 and 2025, we had nil and one franchisee operate under a different brand name, “Geni” or “歌妮”. XinZhan has entered into supplemental agreements with one franchisee that operate stores under a different brand name, pursuant to which each such franchisee is allowed to keep the existing store name and does not have to change the store name to “Park Ha”. The franchisees operating under the “Geni” or “歌妮” brand sell products from the “Park Ha” brand and other third-party brands with XinZhan’s permission.

 

Our operating subsidiaries specialize in providing skincare and cosmetic products under our brand name “Park Ha” in China. Our operating subsidiaries develop our proprietary beauty products and offer complimentary after-sales beauty services in our physical stores. Park Ha Jiangsu, in addition to operating our six physical stores, is the research and development center focusing on skincare products development and improvement for sensitive skin. XinZhan leads the marketing and promotional efforts and is the entity in charge of our franchising business. Park Ha Shanghai is a training center for our franchisee staff. As part of our value-added service for our products, our directly operated stores and franchisees offer “light beauty experience”, a quick complimentary after-sales beauty service performed in the stores. Light beauty experience is offered to our customers as an effective way to demonstrate how our products are used in order to deliver the intended results.

 

Our revenues mainly consist of (i) products sales and (ii) franchise fees. Our total revenue increased by $18,492 to $1,257,689 for the six months ended April 30, 2026 from $1,239,197 for the six months ended April 30, 2025. Products sales accounted for 57% of the total revenue and franchise fees accounted for 43% of the total revenue for the six months ended April 30, 2026. Products sales accounted for 33% of the total revenue and franchise fees accounted for 67% of the total revenue for the six months ended April 30, 2025.

 

As of April 30, 2026, the 21 franchisees locate in the following regions: 16 in Jiangsu Province, 2 in Shandong Province, 1 in Liaoning Province, 1 in Shanxi Province, and 1 in Heilongjiang Province, forming a complete commercial network.

 

As of April 30, 2025, the 39 franchisees locate in the following regions: 22 in Jiangsu Province, 4 in Shandong Province, 3 in Shaanxi Province, 1 in Anhui Province, 1 in Liaoning Province, 1 in Shanxi Province, 1 in Hainan Province, 1 in Henan Province, 1 in Heilongjiang Province, 1 in Guizhou Province, 1 in Zhejiang Province, 1 in Tianjin, and 1 in Hebei Province, forming a complete commercial network.

 

 

 

Factors Affecting Our Results of Operations

 

Our operating subsidiaries currently derive a majority of their revenues from the sale of products and receipt of franchise fees. Park Ha intends to continually enhance its services and cross-sell new services to existing customers and acquire new customers by increasing market penetration with a deeper market coverage and broader geographical reach. Maintaining and enhancing the recognition, image and acceptance of our brand are important to Park Ha’s ability to differentiate our products from and to compete effectively with our peers. Our brand image, however, could be jeopardized if we fail to maintain high product quality, pioneer and keep pace with evolving technology trends, or timely fulfill the orders for our products. If we fail to promote our brand or to maintain or enhance our brand recognition and awareness among our customers, or if we are subject to events or negative allegations affecting our brand image or the publicly perceived position of our brand, our business, results of operations and financial condition could be adversely affected.

 

Our business is in the beauty industry, which is now experiencing rapid technological and model changes. Failure to anticipate technological innovations or adapt to such innovations in a timely manner, or at all, may result in our products and services becoming obsolete or suffering unpredictable intervals.

 

We monitor a number of financial and non-financial key business metrics to evaluate on a regular basis business, growth trends and company budgets, measure the effectiveness of our sales and marketing efforts, and assess operational efficiencies. We believe that some of the most important measures include gross profit margin, operating margin, net income (loss) as well as the non-financial key metrics discussed below which may differ from other similarly titled metrics used by other companies, securities analysts or investors.

 

Number of contracts for our franchisees

 

We monitor the number of contracts with customers for our franchisees. The number of contracts will directly impact our results of operations, including revenues and gross profit margins for the foreseeable future. As of April 30, 2026 and 2025 we had 21 and 39 franchisees in China, of which 21 and 38 franchisees operate under the store name “Park Ha”. As of April 30, 2026 and 2025, we had nil and one franchisee operate under a different brand name. XinZhan has entered into supplemental agreements with one franchisee that operate stores under a different brand name, pursuant to which each such franchisee is allowed to keep the existing store name and does not have to change the store name to “Park Ha” .The business relationships between us and our independent franchisees are built on our standards and policies that is of fundamental importance to the overall performance and protection of the “Park Ha” brand.

 

Expansion of our geographic coverage

 

We believe there is a substantial opportunity to further grow our customer base by continuing to make significant investments in sales, marketing and brand building. Our ability to attract new customers will depend on a number of factors, including competitive dynamics in our targeted new geographical markets in China. We intend to expand our marketing and sales team with a focus on increasing sales in targeted geographies and customer segments. This will play a pivotal role in driving the company’s growth in terms of sales revenue and franchise fee revenue.

 

2

 

 

Results of Operations

 

For the six months ended April 30, 2026 and 2025

 

The following table presents a summary of the Company’s comprehensive operating performance for the six months ended April 30, 2026 and 2025.

 

The historical performance listed below does not necessarily indicate expected performance for any future period.

 

    For the six months ended
April 30,
    Change  
    2026     2025     Amount     %  
Revenues, net     1,257,689       1,239,197       18,492       1 %
Cost of revenues     45,719       58,500       (12,781 )     (22 )%
Gross profit     1,211,970       1,180,697       31,273       3 %
Selling and marketing expenses     560,577       229,775       330,802       144 %
General and administrative expenses     1,189,274       20,632,549       (19,443,275 )     (94 )%
Research and development expenses     138,618       26,087       112,531       431 %
Allowance for expected credit losses     286,048       7,883       278,165       3,259 %
Operating loss     (962,547 )     (19,715,597     18,753,050       (95 )%
Other income (expenses)     (16,437     58,154       (74,591 )     (128 )%
Interest income     49,486       416       49,070       11796 %
Interest (expenses)     (4 )     (20     16       (80 )%
Total other income (expenses)     33,045       58,550       (25,505 )     (44 )%
Loss before tax     (929,502 )     (19,657,048     18,727,546       (95 )%
Income tax (benefit) expense     (11,220 )     178,946       (190,166 )     (106 )%
Net loss     (918,282 )     (19,835,994 )     18,917,712       (95 )%

 

Revenue

 

The sales revenue consists of the following:

 

    For the six months ended     Change  
    April 30,
2026
    April 30,
2025
    Amount     %  
Products sales – Non-franchisees     600,022       48 %     208,701       17 %     391,321       188 %
Product sales – Franchisees     116,083       9 %     195,737       16 %     (79,654 )     (41 )%
Franchise fees     541,584       43 %     834,759       67 %     (293,175 )     (35 )%
Amount     1,257,689       100 %     1,239,197       100 %     18,492       1 %

 

Direct costs consist of the following:

 

    For the six months ended     Change  
    April 30,
2026
    April 30,
2025
    Amount     %  
Products sales – Non-franchisees     28,077       62 %     10,316       18 %     17,761       172 %
Product sales – Franchisees     16,627       36 %     37,566       64 %     (20,939 )     (56 )%
Franchise fees     1,015       2 %     10,618       18 %     (9,603 )     (90 )%
Amount     45,719       100 %     58,500       100 %     (12,781     (22 )%

 

3

 

 

The gross profit consists of the following:

 

    For the six months ended     Change  
    April 30,
2026
    April 30,
2025
    Amount     %  
Products sales – Non-franchisees     571,945       47 %     198,385       17 %     373,560       188 %
Product sales – Franchisees     99,456       8 %     158,171       13 %     (58,715 )     (37 )%
Franchise fees     540,569       45 %     824,141       70 %     (283,572 )     (34 )%
Amount     1,211,970       100 %     1,180,697       100 %     31,273       3 %

 

The gross profit margin consists of the following:

 

    For the six months ended     Change  
    April 30,
2026
    April 30,
2025
    %  
Products sales – Non-franchisees     95 %     95 %            - %
Product sales – Franchisees     86 %     81 %     5 %
Franchise fees     99 %     99 %     - %
Amount     96 %     95 %     1 %

 

For the six months ended April 30, 2026, our total revenue was $1,257,689, while for the six months ended April 30, 2025, our total revenue was $1,239, 197, increased by $18,492, or 1%, which was primarily attributable to the growth in products sales revenue.

 

Our products sales revenue increased by $311,667, or 77%, from $404,438 for the six months ended April 30, 2025 to $716,105 for the six months ended April 30, 2026, which is mainly because with the improvement of the company’s brand awareness, the sales business is in the trend of increasing year by year.

 

Our Franchise fees revenue decreased by $293,175, or 35%, from $834,759 for the six months ended April 30, 2025 to $541,584 for the six months ended April 30, 2026, which is mainly because the decrease of franchisees.

 

4

 

 

Products sales — Non-franchisees

 

Product sales revenue from non-franchisees increased by $391,321, or 188%, from $208,701 for the six months ended April 30, 2025 to $600,022 for the six months ended April 30, 2026. Sales revenue from non-franchisees accounted for 48% and 17% of the total revenue, respectively, for the six months ended April 30, 2026 and 2025. The main drivers are the rising brand awareness, which has boosted sales, and the continuous expansion of our non-franchise outlets.

 

The cost of products sales to non-franchise for the six months ended April 30, 2026 was $28,077, increased by $17,761 or 172% compared to $10,316 for the six months ended April 30, 2025. For the six months ended April 30, 2026 and 2025, cost of products sales to non-franchisees accounted for 62% and 18% of the total cost of revenue, respectively. The higher cost of revenue was primarily driven by rising sales, which led to a synchronous growth in related expenses.

 

For the six months ended April 30, 2026 and 2025, gross profit of products sales to non-franchisees accounted for 47% and 17% of the total gross profit, respectively. For the six months ended April 30, 2026, gross profit and gross profit margin were $571,945 and 95%, respectively, while for the six months ended April 30, 2025, gross profit and gross profit margin were $198,385 and 95%, respectively.

 

Product sales — Franchisees

 

Product sales revenue from franchisees decreased by $79,654, or 41%, from $195,737 for the six months ended April 30, 2025 to $116,083 for the six months ended April 30, 2026. Sales revenue from franchisees accounted for 9% and 16% of the total revenue, respectively, for the six months ended April 30, 2026 and 2025.The decline was primarily attributable to fewer franchise stores.

 

The cost of products sales to franchisees for the six months ended April 30, 2026 was $16,627 representing an decrease of $20,939, or 56%, compared to $37,566 for the six months ended April 30, 2025. For the six months ended April 30, 2026 and 2025, the cost of products sales to franchisees accounted for 36% and 64% of the total cost of revenue, respectively. The above decrease in cost of revenue was mainly due to lower sales volumes.

 

For the six months ended April 30, 2026 and 2025, gross profit of products sales to franchisees accounted for 8% and 13% of the total gross profit, respectively. The gross profit and gross profit margin for the six months ended April 30, 2026 were $99,456 and 86%, respectively. The gross profit and gross profit margin for the six months ended April 30, 2025 were $158,171 and 81%, respectively. which is mainly because the decrease of franchisees.

 

Franchise fees

 

For the six months ended April 30, 2026, the total revenue from franchise fees was $541,584, with a cost of franchise fees of $1,015, compared to $834,759 and $10,618 for the six months ended April 30, 2025. Gross profit of franchise fees decreased by $283,572 for the same period. For the six months ended April 30, 2026 and 2025, the total revenue from franchise fees accounted for 43% and 67% of the total revenue, respectively. For the six months ended April 30, 2026 and 2025, the cost of franchise fees accounted for 2% and 18% of the total cost of revenue, respectively. For the six months ended April 30, 2026 and 2025, the gross profit of franchise fees accounted for 45% and 70% of the total gross profit. The main reason is that:

 

Roll-forward of franchisees

 

The following table provides a roll-forward of our franchise contracts during the six months ended April 30, 2026 and 2025:

 

    Number of                 Number of  
    Franchise                 Franchise  
    Contracts                 Contracts  
    at the     Number of     Number of     at the  
    Beginning of     Newly Joined     Terminated     End of  
    Period     Franchisees     Franchisees     Period  
For the six months ended April 30, 2025     45       2       8       39  
For the six months ended April 30, 2026     22         _     1       21  

 

5

 

 

As of April 30, 2026, the decrease in the number of franchise contracts was primarily attributable to the Company’s adjustment and upgrade of its franchise business model. The Company has implemented enhanced franchisee admission criteria and more rigorous ongoing performance evaluation standards, focusing on improving the operational quality of existing franchisees rather than expanding the number of franchisees. In particular, the Company discontinued or did not renew relationships with franchisees that did not meet its updated criteria

 

As of April 30, 2026, we had 21 franchisees in total, down from 22 at the beginning of the year. The reduction resulted from certain franchisees voluntarily terminated their contracts by electing not to renew.

 

For the six months ended April 30, 2026, all revenue was derived from existing franchisees.

 

As of April 30, 2025, we had 39 franchisees as a result of (i) 33 franchisees renewed their contracts (“2025 Renewed Franchisees”) and 4 franchisees terminated their contracts in May 2025; (ii) 2 newly contracted franchisees.

 

The revenue for the six months ended April 30, 2025 comprised the revenue from (i) 2025 Renewed Franchisees of US$748,993, and (ii) newly contracted franchisees of US$8,253.

 

Our franchise fees are recognized over the franchise term as the performance obligation is satisfied, typically spanning one year. For details, see “Note 2 — Summary of Significant Accounting Policies — Revenue Recognition.” The revenue for the six months ended April 30, 2026 decreased by appropriately 35% as compared to the six months ended April 30, 2025. the decrease in the number of franchise contracts was primarily attributable to the Company’s adjustment and upgrade of its franchise business model.

 

Cost of franchise fees mainly includes the training service cost , advertising support provided and related taxes for franchisees. For the six months ended April 30, 2026, only relevant taxes and fees have been incurred for franchise expenses, and no other costs have been incurred.

 

Selling and marketing expenses

 

For the six months ended April 30, 2026, our selling and marketing expenses were $560,577 , while for the six months ended April 30, 2025, our selling and marketing expenses were $229,775, representing an increase of $330,802, or 144%. The main reason for the increase is (i) the increase of $97,258 in payroll expenses based on the increased directly-operated store and increased sales staff and increased annual bonuses;(ii)Due to business expansion, promotion and advertising expenses have increased by $174,077 and $11,937, respectively (iii)Depreciation expenses increased by approximately $38,894.

 

6

 

 

General and administrative expenses

 

For the six months ended April 30, 2026, our general and administrative expenses were $ 1,189,274 , while for the six months ended April 30, 2025, our general and administrative expenses were $20,632,549, representing a decrease of $19,443,275 or 94%. The decrease was primarily attributable to the share-based payment expense of $19,950,000 recognized for the six months ended April 30, 2025 in connection with the immediately vested 2025 Share Incentive Award, while no such expense was recognized for the six months ended April 30, 2026.

 

Research and development expenses

 

For the six months ended April 30, 2026 our R&D expenses were $138,618, while for the six months ended April 30, 2025, our R&D expenses were $26,087, representing an increase of $112,531. The primary reason is the addition of $90,000 in outsourced R&D costs during this period.

 

Allowance for expected credit losses

 

Allowance for expected credit losses derives from allowances on accounts receivable and loan receivable from franchisees, based on past collection experience, current economic conditions, future economic conditions and changes in the Company’s customer collection trends. Allowance for expected credit losses of accounts receivables and franchisee loan and other receivables were $286,048 for the six months ended April 30, 2026, representing a increase of $278,165 or 3,529% from $7,883 for the six months ended April 30, 2025.

 

Allowance for accounts receivables decreased from $144,859 as of October 31, 2025 to $151,003 as of April 30, 2026, an increase of $6,144 or 4%. No significant changes have occurred.

 

Allowance for loans receivables from franchisees increased from $232,876 as of October 31, 2025 to $534,173 as of April 30, 2026, an increase of $301,297 or 129%. primarily due to the increase of past-due loans.

 

Allowance for other receivables decreased from $11,002 as of October 31, 2025 to $11,468 as of April 30, 2026, an increase of $466 or 4%. No significant changes have occurred.

 

Interest income (expense)

 

Interest income mainly comes from deposit interest income. Interest income for the six months ended April 30, 2026 and 2025 was approximately $49,486 and $416, respectively.

 

Interest expense mainly comes from the bank transfer fees. Interest expense for the six months ended April 30, 2026 and 2025 was approximately $(4) and $(20), respectively.

 

7

 

 

Income tax expense (benefit)

 

The Company in general is subject to profits tax rate at 25% for income generated for its operation in China and net operating losses can be carried forward for no longer than five years starting from the year subsequent to the year in which the loss was incurred.

 

In accordance with the implementation rules of EIT Laws, a qualified “High and New Technology Enterprise” (“HNTE”) is eligible for a preferential tax rate of 15%. The HNTE certificate is effective for a period of three years. An entity could re-apply for the HNTE certificate when the prior certificate expires. “Park Ha Jiangsu” obtained its HNTE certificate on November 6, 2024. Therefore, “Park Ha Jiangsu” is eligible to enjoy a preferential tax rate of 15% from 2024 to 2026 to the extent it has taxable income under the EIT Law.

 

Announcement No. 12 [2023] of the Ministry of Finance and the State Taxation Administration stipulates that the preferential corporate income tax (CIT) policy for small and low-profit enterprises (SLPEs) — reducing taxable income by 25% and applying a 20% tax rate — shall be extended until December 31, 2027.Wuxi Muchen and Wuxi Mufeng and ParkHa Investment , with annual taxable income not exceeding RMB 1 million for the year ended October 31, 2025, qualify as SLPEs. As such, 25% of their taxable income is subject to CIT at the reduced rate of 20%.

 

Ai Meihui obtained the “Review Approval Notification for Application and Adjustment of Fixed Amount for Periodic Fixed-Amount Taxpayers” issued by the State Taxation Administration, Jiangsu Wuxi Economic Development Zone Tax Bureau on August 30, 2025, indicating that the application for “Periodic Fixed-Amount Taxpayer Application and Adjustment of Fixed Amount” submitted by Ai Meihui on August 22, 2025, has been approved. Upon review, Ai Meihui’s account shall implement a monthly taxable amount of 0.0 yuan from August 1, 2025, to December 31, 2025. As of April 30, 2026, the taxable amount assessed by the tax authority under the periodic fixed-amount collection method is nil

 

Xinyuexuan obtained the “Review Approval Notification for Application and Adjustment of Fixed Amount for Periodic Fixed-Amount Taxpayers” issued by the State Taxation Administration, Jiangsu Wuxi Economic Development Zone Tax Bureau on August 19, 2025, indicating that the application for “Periodic Fixed-Amount Taxpayer Application and Adjustment of Fixed Amount” submitted by Xinyuexuan on August 11, 2025, has been approved. Upon review, Xinyuexuan’s account shall implement a monthly taxable amount of zero yuan from July 1, 2025, to December 31, 2025. As of April 30, 2026, the taxable amount assessed by the tax authority under the periodic fixed-amount collection method is nil

 

Hefeng received a “Reminder of Approval for Periodic Fixed-Amount Taxpayer’s Application for Assessment and Adjustment of Fixed Quota” issued by the Tax Service Office of Wuxi Economic Development Zone of the State Administration of Taxation on January 13, 2026. The application for “Periodic Fixed-Amount Taxpayer’s Application for Assessment and Adjustment of Fixed Quota” filed by Hefeng on January 5, 2026, has been approved. As a result, Hefeng is subject to a monthly taxable amount of RMB 0.00 for the period from January 1, 2026 to December 31, 2026, as assessed by the tax authority.

 

The income tax (benefit) expense for the six months ended April 30, 2026 and 2025 were approximately $(11,220) and $178,946, respectively.

 

The income tax expense for the fiscal year ended April 30, 2026 was adjusted by (i)the increase in the income tax expense by $173,133, of which $26,100 because Park Ha Jiangsu enjoyed a preferential rate of 15%, of which $154,755 because Park Ha Cayman is not subject to tax, of which $14,496 because Wuxi Muchen, Wuxi Mufeng and ParkHa Investment enjoyed a preferential rate of 5% for small and Low-Profit Enterprises, of which $(22,218) because HeFeng,Aimei Hui and Xinyuexuan enjoyed Deemed Provision Tax Assessment; (ii)the decrease in the income tax expense of $22,806 due to the effect of super deduction of R&D expenses of $121,366; and (iii)the increase in the income tax expense of 68,374 because Park Ha Jiangsu , Park Ha Shanghai ,Wuxi Muchen ,Wuxi Mufeng , ParkHa Investment and Wuxi MaoHe recorded net loss for the fiscal year ended April30, 2026;and (iv)the increase in the income tax expense of $2,454 due to the effect of entertainment expenses of $10,547.

 

The income tax expense for the six months ended April 30, 2025 was adjusted by (i) the increase in the income tax expense by $5,059,645, of which $19,132 because Park Ha Jiangsu enjoyed a preferential rate of 15%, of which $5,045,947 because Park Ha Cayman is not subject to tax, of which $(4221) because Wuxi Muchen and Wuxi Mufeng enjoyed a preferential rate of 5% for small and Low-Profit Enterprises, of which $(1213) because Huishan Yiyayue enjoyed a preferential rate of 3% for Individual Businesses (Self-Employed); (ii) the decrease in the income tax expense of $3,913 due to the effect of super deduction of R&D expenses of $26,087; and (iii) the increase in the income tax expense by 35,614 because Park Ha Jiangsu and Park Ha Shanghai recorded net loss for the six months ended April 30, 2025; and (iv) the increase in the income tax expense of $1,862 due to the effect of non-deductible expense of $12,295.

 

8

 

 

Net Loss

 

As a result of the foregoing, for the six months ended April 30, 2026, our net loss was $918,282, compared to net loss $19,835,994 for the six months ended April 30, 2025, representing a decrease of $18,917,712 or 95%.

 

Working capital and capital resources

 

As of April 30, 2026, we had $627,851 in cash as compared to $3,787,678 as of October 31, 2025. The Company’s working capital and other capital needs mainly come from shareholders’ equity contributions and operating cash flows. Cash is needed to pay for inventory, wages, sales expenses, rent, income tax, and other operating expenses.

 

Although the Company’s management believes that the cash generated from operations will be sufficient to meet the Company’s normal working capital needs, its ability to service its current debts will depend on its future realization of its current assets for at least the next 12 months. The management has considered historical experience, economic conditions, trends in the beauty industry, the collectability of accounts receivable as of April 30, 2026, and the realization of inventory. Based on these considerations, the management believes that the Company has sufficient funds to meet its working capital needs and debt obligations, as they will be due at least 12 months from the date of financial reporting. However, there is no guarantee that the management’s plan will be succeed. There are many factors that may occur and cause the Company’s plan to fall short, such as economic conditions, competitive pricing in the industry and the continuous support of our suppliers. If future operating cash flows and other capital resources are insufficient to meet its liquidity needs, the Company may be forced to reduce or postpone its anticipated expansion plans, sell assets, acquire additional debt or equity capital, or refinance all or part of its debt.

 

The following table summarizes the Company’s cash flow data for the six months ended April 30, 2025 and 2024:

 

 

    For the six months ended
April 30,
 
    2026     2025  
Net cash (used in) provided by operating activities   $ (113,727 )   $ 245,433  
Net cash used in investing activities     5,354,658       3,262,430  
Net cash provided by financing activities     2,236,811       3,833,511  
Net (decrease) increaseof cash     (3,231,574 )     816,514  
Effect of foreign currency translation     71,747       (12,727 )
Cash – beginning of period     3,787,678       547,498  
Cash – end of period   $ 627,851     $ 1,351,285  

 

Net cash (used in) provided by operating activities

 

For the six months ended April 30, 2026, the net cash used in operating activities was $113,727, as compared to the net cash provided by operating activities of $245,433 for the six months ended April 30, 2025. Key drivers of the change include:(i) increase in fluctuations of other receivables and other current assets of $239,684.(ii) increase in fluctuations of contractual liabilities of $192,970 .(iii) increase in fluctuations of accounts receivable of $43,912, (iv) increase in fluctuations of accounts payable of $8,973 and (v)decrease in fluctuations of Taxes payable of $141,859.

 

9

 

 

Net cash used in investing activities

 

For the six months ended April 30, 2026, the net cash used in investment activities was $5,354,658, as compared to the net cash used in investment activities of $3,262,430 for the six months ended April 30, 2025. The increase in net cash used in investment activities is mainly due to the short term investments $ 5,018,889 .

 

Net cash provided by financing activities

 

For the six months ended April 30, 2026, the net cash provided by financing activities was $2,236,811, as compared to the net cash provided by financing activities of $3,833,511 for the six months ended April 30, 2025. The main reason for the decrease in net cash from financing activities is the decrease in cash inflows from stock issuances compared to the same period last year.

 

Non-cash lease expenses

 

As of April 30, 2026, the Company has entered into several operating leases for its self-operated stores, dormitories and offices. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its leases as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.

 

Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is incremental borrowing rate or, if available, the rate implicit in the lease.

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

 

    For the Six Months End  
    April 30,  
    2026     2025  
Lease Cost            
Operating lease cost   $ 52,027     $ 14,098  
                 
Other Information                
Cash paid for amounts included in the measurement of lease liabilities   $ 46,988     $ 13,422  

 

As of April 30, 2026 and October 31, 2025, the weighted average lease term and discount rate are as follows:

 

    April 30,
2026
    October 31,
2025
 
Weighted average remaining lease term – operating leases (in years)     2.05       2.47  
Average discount rate – operating lease     3.21 %     3.25 %

 

10

 

 

As of April 30, 2026 and October 31, 2025, the supplemental balance sheet information related to leases are as follows:

 

    April 30,
2026
    October 31,
2025
 
Operating leases            
Right-of-use assets   $ 181,274     $ 180,243  
                 
Operating lease liabilities, current   $ 128,432     $ 104,254  
Operating lease liabilities, non-current     57,899     $ 75,915  
Total operating lease liabilities   $ 186,331     $ 180,169  

 

The undiscounted future minimum lease payment schedule as follows:

 

For the years ending April 30,      
Due and unpaid for 2025     12,304  
Remainder of 2026     74,352  
2027     76,837  
2028     28,308  
Total undiscounted lease payments     191,801  
Less imputed interest     (5,470 )
Total lease liabilities     186,331  

 

Concentration of credit risk

 

Cash deposits with banks are held in financial institutions in China, which deposits are not federally insured. Accordingly, the Company has a concentration of credit risk related to the uninsured part of bank deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk.

 

Concentration of customers and suppliers

 

Cash deposits with banks are held in financial institutions in China, which deposits are not federally insured. Accordingly, the Company has a concentration of credit risk related to the uninsured part of bank deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk.

 

Concentration of customers and suppliers

 

The Company has a concentration risk related to suppliers and customers. Failure to maintain existing relationships with the suppliers or customers to establish new relationships in the future could negatively affect the Company’s ability to obtain goods sold to customers in a price advantage and timely manner. If the Company is unable to obtain ample supply of goods from existing suppliers or alternative sources of supply, the Company may be unable to satisfy the orders from its customers, which could materially and adversely affect revenues.

 

For the six months ended of April 30, 2026, the company’s customers are relatively scattered, with no single customer accounting for more than 10% of total revenue.

 

The customers that accounted for 10% or more of the Company’s accounts receivable comprised of the following:

 

    April 30,
2026
    October 31,
2025
 
Percentage of the Company’s accounts receivable            
Customer D     11 %     4 %
Customer J     50 %     28 %
Customer L     %     11 %
Customer K     28 %     15 %

 

11

 

 

The suppliers that accounted for 10% or more of the Company’s purchases comprised of the following:

 

    For the Six Months Ended  
    April 30,
2026
    April 30,
2025
 
Percentage of the Company’s purchases            
Supplier A     8 %     12 %
Supplier B     11 %     12 %
Supplier C     9 %     13 %
Supplier D     %     %
Supplier E     6 %     14 %
Supplier F     18 %     %
Supplier I     7 %     11 %
Supplier J     5 %     11 %

 

The suppliers that accounted for 10% or more of the Company’s account payables comprised of the following:

 

    April 30,
2026
    October 31,
2025
 
Percentage of the Company’s accounts payable            
Supplier E     11 %     %
Supplier G     56 %     81 %
Supplier H     16 %     19 %
Supplier J     14 %     %

 

Contract liability

 

The contract liabilities consist of advances from customers, which relate to unsatisfied performance obligations at the end of each reporting period and consists of cash payments received in advance from customers in sales of beauty products and devices and unearned franchise fee. As of April 30, 2026 and October 31, 2025, the Company’s advances from customer deposit and unearned franchise fee amounted to $194,968 and $194,753, respectively.

 

Trend Information

 

Except as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events that may reasonably be likely to have a significant impact on our net income, income from continuing operations, profitability, working capital or capital resources, or that would cause reported may not necessarily to be indicative of future operating results or financial condition.

 

Off-Balance Sheet Arrangements

 

Except as disclosed elsewhere in this annual report, we have not entered into any financial guarantees or other commitments to ensure the payment obligations of any third party. We have not entered into any derivative contracts that are indexed to its shares and classified as shareholders ’ equity or that are not reflected in its consolidated financial statements. In addition, we do not have any retained or contingent interests in the assets transferred to unconsolidated entities that services as credit, liquidity, or market risk support to such entities. We do not have any variable interests in any unconsolidated entity that provides us with financing, liquidity, market risk or credit support, or that engages in leasing, hedging or research and development services.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements. These financial statements are prepared in accordance with U.S. GAAP, which requires us to make estimates and assumptions that affect the reported amounts of our assets and liabilities and revenue and expenses, to disclose contingent assets and liabilities on the date of the consolidated financial statements, and to disclose the reported amounts of revenue and expenses incurred during the financial reporting period. The most significant estimates and assumptions include the assessment of the expected credit losses for receivables. We continue to evaluate these estimates and assumptions that we believe to be reasonable under the circumstances. We rely on these evaluations as the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from those estimates. Some of our accounting policies require higher degrees of judgment than others in their application. We believe critical accounting policies as disclosed in this annual report reflect the more significant judgments and estimates used in preparation of our consolidated financial statements.

 

12

 

 

The following critical accounting policies rely upon assumptions and estimates and were used in the preparation of our consolidated financial statements:

 

Credit Losses

 

On January 1, 2023, we adopted Accounting Standards Update (“ASU”) 2016-13 “Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments,” by using a modified retrospective transition method, which replaces the incurred loss impairment methodology with an expected loss methodology that is referred to as the current expected credit loss methodology. The expected credit loss impairment model requires the entity to recognize its estimate of expected credit losses for affected financial assets using an allowance for credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The adoption of ASU 2016-13 did not have a material impact on our financial statements.

 

Our account receivables, loans receivable from franchisees, due from related parties and other receivables which is included in other receivables and other current assets line item in the balance sheet are within the scope of ASC Topic 326. We use the roll-rate method to measure expected credit losses of account receivables and loans receivable from franchisees, on a collective basis when similar risk characteristics exist. The roll-rate method stratifies the receivables balance by delinquency stages and projected forward in one-year increments using historical roll rate. In each year of the simulation, losses on the receivables are captured, and the ending delinquency stratification serves as the beginning point of the next iteration. This process is repeated on a yearly rolling basis. The loss rate calculated for each delinquency stage is then applied to respective receivables balance. The management adjusts the allowance that is determined by the roll-rate method for both current conditions and forecasts of economic conditions. For due from related parties and other receivables, we use the loss-rate method to evaluate the expected credit losses on an individual basis. When establishing the loss rate, we make the assessment on various factors, including historical experience, creditworthiness of debtors, current economic conditions, reasonable and supportable forecasts of future economic conditions, and other factors that may affect its ability to collect from the debtors. We also provide specific provisions for allowance when facts and circumstances indicate that the receivable is unlikely to be collected.

 

Expected credit losses are included in the consolidated statements of operations and comprehensive income. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Account receivables, loans receivable from franchisees, due from related parties and other receivables are recognized and carried at original amount less an allowance for credit losses, as necessary. As of April 30,2026, and October 31, 2025, allowance for credit losses for accounts receivable amounted to $151,003 and $144,859, respectively, allowance for credit losses for loans to franchisees amounted to $534,173, and $232,876, respectively, and allowance for credit losses for other receivables amounted to $11,468 and $11,002, respectively.

 

Quantitative and qualitative disclosure of market risk

 

The deterioration of the overall economic conditions in the United States and globally, including the impact of long-term deflation on our customers and suppliers, may harm our business and operational results.

 

Our business and operating results may be adversely affected by changes in national or global economic conditions. These situations include but are not limited to inflation and/or deflation, changes in interest rates, availability of capital markets, availability and cost of energy (including fuel surcharges), negative impacts caused by military conflicts between Russia and Ukraine, and the impact of government measures to manage economic conditions. The impact of such situations may be transmitted to our business in the form of a decrease in customer base and/or our customer expenses, as industry wide expenses may decrease and/or our suppliers may face economic pressure to shift costs.

 

Risks related to conducting business in China

 

The intervention of the state government in the commercial activities of Chinese companies listed in the United States may have a negative impact on our operations.

 

The Chinese government announced that it will strengthen regulation of Chinese companies listed overseas. According to the new measures, China will strengthen the supervision of cross-border data flow and security, crack down on illegal activities in the securities market, punish fraudulent securities issuance, market manipulation, and insider trading. China will also inspect the sources of funds for securities investment and control leverage. The Cyberspace Administration also conducted cybersecurity investigations on several technology giants listed in the United States, with a focus on antitrust, fintech regulation, and with the passage of the Data Security Law, how companies collect, store, process, and transfer data. Our operations and commercial interests are in Chinese Mainland. If the intervention of the Chinese government is expanded and through agency, our commercial interests will be affected, and our operations may be negatively affected, although there is currently no obvious direct impact.

 

13

 

Exhibit 99.2

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Unaudited Interim Condensed Consolidated Balance Sheets

As of April 30, 2026 and October 31, 2025

 

   

April 30,

2026

   

October 31,

2025

 
             
ASSETS            
Current Assets            
Cash and cash equivalents     627,851       3,787,678  
Short-term investment     5,029,644      
 
Accounts receivable, net     16,768       255,844  
Due from related parties     769       35  
Inventories     104,046       75,214  
Advances to suppliers     11,278       9,384  
Loans receivable from franchisees, net     885,861       1,021,181  
Other receivables and other current assets     106,787       352,626  
Total current assets     6,783,004       5,501,962  
Non-current Assets                
Property and equipment, net     297,435       157,999  
Intangible assets, net     6,408       6,639  
Operating lease right of use asset     181,274       180,243  
Other non-current assets     192,975       105,773  
Total non-current assets     678,092       450,654  
TOTAL ASSETS     7,461,096       5,952,616  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current liabilities                
Accounts payable     14,775       12,013  
Due to related parties    
      7,026  
Taxes payable     1,511,768       1,375,488  
Operating lease liabilities – current     128,432       104,254  
Contract liability     194,968       194,753  
Accruals and other payables     165,964       188,312  
Total current liabilities     2,015,907       1,881,846  
Non-current liabilities                
Operating lease liabilities – non-current     57,899       75,915  
Total non-current assets     57,899       75,915  
TOTAL LIABILITIES     2,073,806       1,957,761  
                 
Commitments and contingencies    
     
 
                 
Shareholders’ equity                
Class A Ordinary Shares, $0.001 par value; 12,000,000,000 shares authorized;  4,543,884 and  296,488  shares issued and outstanding as of April 30, 2026, and October 31, 2025, respectively;*     4,544       296  
Class B Ordinary Shares, $0.001 par value; 3,000,000,000 shares authorized; 381,000 shares issued and outstanding as of April 30, 2026, and October 31, 2025, respectively*     381       381  
Additional paid in capital     30,261,334       28,021,581  
Statutory reserve     217,264       217,264  
Accumulated deficits     (25,096,549 )     (24,178,267 )
Accumulated other comprehensive income (loss)     316       (66,400 )
Total shareholders’ equity     5,387,290       3,994,855  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY     7,461,096       5,952,616  

 

 

* Retroactively restated to reflect the share split, reverse share split and share reorganization (See Note 15).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  F-1  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Income

For the Six Months Ended April 30, 2026 and 2025

 

   

Six Months

Ended

April 30,

2026

   

Six Months

Ended

April 30,

2025

 
Revenues, net     1,257,689       1,239,197  
Cost of revenues     45,719       58,500  
Gross profit     1,211,970       1,180,697  
                 
Operating expenses                
Selling and marketing expenses     560,577       229,775  
General and administrative expenses     1,189,274       20,632,549  
Research and development expenses     138,618       26,087  
Allowance for expected credit losses     286,048       7,883  
Total operating expenses     2,174,517       20,896,294  
Operating loss     (962,547 )     (19,715,597 )
                 
Non-operating income (expense) items:                
Other income (expense)     (16,437 )     58,154  
Interest income     49,486       416  
Interest (expense)     (4 )     (20 )
Total other income, net     33,045       58,550  
                 
Loss before income tax     (929,502 )     (19,657,048 )
                 
Income tax (benefit) expense     (11,220 )     178,946  
                 
Net loss     (918,282 )     (19,835,994 )
                 
Other comprehensive income (loss) :                
Foreign currency translation adjustment     66,716       (9,999 )
Total comprehensive loss     (851,566 )     (19,845,993 )
                 
Loss per share                
Ordinary shares – basic and diluted     (0.33 )     (36.89 )
Weighted average shares outstanding used in calculating basic and diluted earnings per share:                
Ordinary shares – basic and diluted     2,801,186       537,744  

 

 

* Retroactively restated to reflect the share split, reverse share split and share reorganization (See Note 15).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  F-2  

 

  

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Unaudited Interim Condensed Consolidated Statements of Changes in Shareholders’ Equity (Deficits)

For the Six Months Ended April 30, 2026 and 2025

 

    Ordinary Shares     Additional        

Retained

Earnings

   

Accumulated

Other

       
   

Number of

Shares

    Amount    

Paid-in

Capital

    Statutory
Reserves
   

(Accumulated

Deficits)

   

Comprehensive

Loss

   

Total

Equity

 
                                           
Balance at October 31, 2024     500,000       500       1,161,211       131,962       271,788       (59,376 )     1,506,085  
Issuance of shares, net     27,488       27       2,640,320      
     
     
      2,640,347  
Share-based Compensation     60,000       60       19,949,940      
     
     
      19,950,000  
Net loss          
     
     
      (19,835,994 )    
      (19,835,994 )
Foreign currency translation adjustment          
     
     
     
      (9,999 )     (9,999 )
Balance at April 30, 2025     587,488       587       23,751,471       131,962       (19,564,205 )     (69,375 )     4,250,440  
                                                         
Balance at October 31, 2025     677,488       677       28,021,581       217,264       (24,178,267 )     (66,400 )     3,994,855  
Issuance of shares, net     4,247,396       4,247       2,239,753                               2,244,000  
Net loss          
     
     
      (918,282 )    
      (918,282 )
Foreign currency translation adjustment          
     
     
     
      66,716       66,716  
Balance at April 30, 2026     4,924,884       4,925       30,261,334       217,264       (25,096,549 )     316       5,387,290  

 

 

 

* Retroactively restated to reflect the share split, reverse share split and share reorganization (See Note 15).

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  F-3  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Unaudited Interim Condensed Consolidated Statements of Cash Flows

For the Six Months Ended April 30, 2026 and 2025

(Unaudited)

 

   

Six Months

Ended

April 30,

2026

   

Six Months

Ended

April 30,

2025

 
Cash flows from operating activities            
Net loss     (918,282 )     (19,835,994 )
Depreciation and amortization     95,282       15,508  
Allowance for credit losses     286,048       7,883  
Allowance for Inventory     (1,760 )      
Impairments and write-offs of assets     134       4,734  
Deferred tax benefits     (71,290 )     (1,993 )
Operating lease expenses     52,027       14,098  
Share-based Compensation Expense           19,950,000  
Non-cash interest income     (10,754 )     (29,000 ) 
Changes in operating assets and liabilities:                
Accounts receivable     245,322       201,410  
Inventories     (23,543 )     (570 )
Advances to suppliers     (1,468 )     16,124  
Other receivables and other current assets     249,183       9,499  
Operating advance payments to related parties     (719 )     (263 )
Other non-current assets     (9,901 )     (3,141 )
Accruals and other payables     (27,831 )     (100,169 )
Accounts payable     2,211       (6,762 )
Taxes payable     76,499       218,358  
Contract liability     (7,897 )     (200,867 )
Operating lease liabilities     (46,988 )     (13,422 )
Net cash (used in) provided by operating activities     (113,727 )     245,433  
Cash flows from investing activities                
Purchase of equipment and intangible assets     (225,065 )     (2,213 )
Loans to franchisees     (573,647 )     (691,377 )
Loan repayment from franchisees     462,943       416,890  
Short-term investments     (5,018,889 )      
Loans to the third party           (3,000,000 )
Repayment from related parties           14,270  
Net cash used in investing activities     (5,354,658 )     (3,262,430 )
                 
Cash flows from financing activities                
Proceeds from shareholder’s contribution of capital            
Proceeds from issuance of shares     2,244,000       4,277,807  
Borrowing from related party           7,462  
Repayment to related parties     (7,189 )      
IPO Costs           (451,758 )
Net cash provided by financing activities     2,236,811       3,833,511  
                 
Net (decrease) increase in cash and cash equivalents     (3,231,574 )     816,514  
                 
Effect of foreign currency translation     71,747       (12,727 )
Cash and cash equivalents– beginning of period     3,787,678       547,498  
Cash and cash equivalents– end of period   $ 627,851     $ 1,351,285  
                 
Supplementary cash flow information:                
Interest paid   $     $  
Income tax paid   $     $  
Non-cash investing and financing activities:                
Non-cash IPO costs           (97,302 )
Non-cash interest (loss) income     (10,754 )     29,000  
Operating lease right-of-use assets obtained in exchange for operating lease liabilities   $ 41,558     $ 34,759  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial.

 

  F-4  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 1 — ORGANIZATION AND BASIS OF PRESENTATION

 

Park Ha Biological Technology Co., Ltd. (“Park Ha Cayman”) was incorporated in the Cayman Islands on October 11, 2022. The Company is an investment holding company; its primary business operations are conducted through its subsidiaries and VIEs as described below.

 

Park Ha Biological Technology (HK) Co., Ltd. (“Park Ha HK”) was incorporated in Hong Kong on October 25, 2022. It is a wholly owned subsidiary of Park Ha Cayman.

 

Park Ha Investment (Wuxi) Co., Ltd. (“Park Ha WFOE”) was incorporated on May 5, 2023 as a wholly foreign owned entity in the People’s Republic of China (“PRC”). Park Ha WFOE is a wholly owned subsidiary of Park Ha HK.

 

Wuxi Xinzhan Enterprise Management Consulting Co., Ltd. (“XinZhan”) was incorporated on March 31, 2016 in the People’s Republic of China (“PRC”) with Ms. Xiaoqiu Zhang being the majority shareholder owning 75.2% of XinZhan prior to the equity transfer described below. XinZhan takes the lead in promoting the franchisee market and looking for franchisees. XinZhan signs a franchise agreement with the franchisee. The franchise agreement grants the franchisee the license to open stores under the “PARK HA” brand in a specific area. Franchisees authorized to sell Park Ha Jiangsu’s “PARK HA” brand products or third-party products authorized by XinZhan must comply with the terms of the franchise agreement.

 

Shanghai Park Ha Industrial Development Co., Ltd. (“Park Ha Shanghai”) was incorporated on April 17, 2017 in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of Wuxi XinZhan. Park Ha Shanghai’s primary business includes beauty services, sales of beauty products and devices, management of beauty salon franchises.

 

Jiangsu Park Ha Biotechnology Co., Ltd. (“Park Ha Jiangsu”) was incorporated on August 13, 2019 in the People’s Republic of China (“PRC”) with Ms. Xiaoqiu Zhang being the majority shareholder owning 75.2% of Park Ha Jiangsu prior to the equity transfer described below. Park Ha Jiangsu has developed a full range of “PARK HA” brand skin care products through cooperation with biological laboratories. Our product range ranges from basic skin physical protection, exfoliation, and sebum film repair to surface microecological balance and anti-aging. These products are sold through directly operated retail stores and franchisees.

 

On May 17, 2023, Park Ha WFOE entered into equity transfer agreements with each shareholder of Wuxi XinZhan and Park Ha Jiangsu to purchase all the equity interest in such entities. The restructure was completed on July 7, 2023. As a result, Wuxi XinZhan and Park Ha Jiangsu became a wholly owned subsidiary of Park Ha WFOE.

 

Upon the completion of the above Reorganization, Park Ha Cayman became the ultimate holding company of all other entities mentioned above. The Company is effectively controlled by the same group of controlling shareholders before and after the Reorganization; therefore, the Reorganization is considered as a recapitalization of these entities under common control. The consolidation of the Company was accounted for at historical cost and prepared on the basis as if the aforementioned transactions had become effective as of the beginning of the first period presented in the accompanying unaudited condensed consolidated financial statements. Results of operations for the period presented comprise those of the previous separate entries combined from the beginning of the period to the end of the period, eliminating the effects of intra-entity transactions.

 

Wuxi Mufeng Biotechnology Co., Ltd (“Wuxi Mufeng”) and Wuxi Muchen Biotechnology Co., Ltd (“Wuxi Muchen”) were incorporated on February 21, 2025 in the People’s Republic of China (“PRC”) as a wholly owned subsidiary of Park Ha Jiangsu.

 

Xinyuexuan Beauty Salon(“xinyuexuan)was incorporated on July 28, 2025 in the Peoples Republic of China (PRC) and is controlled by Park Ha Jiangsu through contractual arrangement as its variable interest entity (VIE).

 

Aimei Hui Beauty Salon(Aimei Hui) was incorporated on August 11, 2025 in the Peoples Republic of China (PRC) and is controlled by Park Ha Jiangsu through contractual arrangement as its VIE.

 

  F-5  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 1 — ORGANIZATION AND BASIS OF PRESENTATION (cont.)

 

Huishan District Xuanyayue (Xuanyayue) was incorporated on January 22, 2025, in the Peoples Republic of China (PRC) and is controlled by Park Ha Jiangsu through contractual arrangement as its VIE. Xuanyayue closed down on October 10, 2025.

 

Hefeng Beautv Salon(Hefeng) was incorporated on November 27, 2025 in the Peoples Republic of China (PRC) and is controlled by Park Ha Jiangsu through contractual arrangement as its VIE.

 

Wuxi Maohe Biotechnology Co., Ltd (Wuxi Maohe) was incorporated on December 3, 2025 in the Peoples Republic of China (PRC) as a wholly owned subsidiary of Wuxi Xinzhan.

 

In support of its business expansion, the Company established four salonsXinyuexuan, Aimei Hui, Xuanyayue, and Hefengduring 2025, in which neither it nor its subsidiaries hold any equity interest. Control over these entities is exercised by Park Ha Jiangsu through contractual arrangements in lieu of direct ownership. Pursuant to these agreements, Park Ha Jiangsu, as the actual capital contributor, is responsible for their operational management and is entitled to all profits as well as bears all losses arising therefrom. Accordingly, the Company consolidates the accounts of these entities for the periods presented herein in accordance with Regulation S-X-3A-02 promulgated by the Securities Exchange Commission (SEC) and Accounting Standards Codification (ASC) 810-10, Consolidation.

 

 Park Ha Biological Technology Co., Ltd., its subsidiaries and VIEs are collectively referred to as the Company.

 

The accompanying unaudited condensed consolidated financial statements reflect the activities of Park Ha Cayman and each of the following entities:

 

Name   Background   Ownership
Park Ha Biological Technology (HK) Co., Ltd.   Incorporated on October 25, 2022 as a limited liability company in Hong Kong   100% owned by Park Ha Cayman
Park Ha Investment (Wuxi) Co., Ltd.   Incorporated on May 5,  2023 as a limited liability company in the PRC   100% owned by Park Ha HK
Jiangsu Park Ha Biological Technology Co., Ltd.   Incorporated on August 13, 2019 as a limited liability company in the PRC   100% owned by Park Ha Investment
Wuxi Xinzhan Enterprise Management Consulting Co., Ltd.   Incorporated on March 31, 2016 as a limited liability company in the PRC   100% owned by Park Ha Investment
Shanghai Park Ha Industrial Development Co., Ltd.   Incorporated on April 17, 2017 as a limited liability company in the PRC   100% owned by Xinzhan
Wuxi Muchen Biotechnology Co., Ltd   Incorporated on February 21, 2025 as a limited liability company in the PRC   100% owned by Park Ha Jiangsu
Wuxi Mufeng Biotechnology Co., Ltd.   Incorporated on February 21, 2025 as a limited liability company in the PRC   100% owned by Park Ha Jiangsu
Xinyuexuan Beauty Salon,Wuxi Economic Development Zone   Incorporated on July 28, 2025   100% agreement control by Park Ha Jiangsu
Aimeihui  Beauty Center,Wuxi Economic Development Zone   Incorporated on August 11, 2025   100% agreement control by Park Ha Jiangsu
Huishan District Xuanyayue Beauty Salon   Incorporated on January 22, 2025  

100% agreement control by Park Ha Jiangsu

(close down on Oct.10 2025)

Hefeng Beautv Salon   Incorporated on November 27, 2025   100% agreement control by Park Ha Jiangsu
Wuxi Maohe Biotechnology Co., Ltd   Incorporated on December 3, 2025   100% owned by Xinzhan

 

  F-6  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the Company’s unaudited condensed consolidated financial statement. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s consolidated financial statements and the notes thereto for the year ended October 31, 2025 included in the other.

 

The accompanying unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries, which include the wholly-foreign owned enterprise (“WFOE”) and VIEs over which the Company exercises control and, when applicable, entities for which the Company has a controlling financial interest or is the primary beneficiary. All transactions and balances among the Company and its subsidiaries have been eliminated upon consolidation. Operating results for the six months ended April 30, 2026, and 2025 are not necessarily indicative of the results that may be expected for the full year.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Significant accounting estimates include certain assumptions related to, among others, the valuation of the amount due from related parties, inventory valuations, the estimation of useful lives of property and equipment and intangible assets, allowance for expected credit losses, and income taxes, including the valuation allowance for deferred tax assets. Actual results could differ from those estimates.

 

Functional and Presentation Currency

 

The functional currency of the Company is the currency of the primary economic environment in which the Company operates, which is Chinese Yuan (“RMB”). The RMB is not freely convertible into the US dollar and may be subject to PRC currency restrictions for payments, including the distributions of dividends or retained earnings to the Company by its subsidiaries.

 

Transactions in currencies other than the entity’s functional currency are recorded at the rates of exchange prevailing on the date of the transaction. At the end of each reporting period, monetary items denominated in foreign currencies are translated at the rates prevailing at the end of the reporting periods. Exchange differences arising on the settlement of monetary items and on translation of monetary items at period-end are included in income statement of the period.

 

For the purpose of presenting these financial statements, the Company’s assets and liabilities are expressed in US$ at the exchange rate on the balance sheet date, shareholder’s equity accounts are translated at historical rates, and income and expense items are translated at the periodic average exchange rate during the period. The resulting translation adjustments are reported under accumulated other comprehensive income (loss) in the shareholder’s equity section of the balance sheets.

 

  F-7  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Exchange rate used for the translation as follows:

 

    As of  
   

April 30,

2026

   

October 31,

2025

 
Period end US$: RMB exchange rate     6.8273       7.1169  

 

    For the six months ended  
    April 30  
    2026     2025  
Period average US$: RMB exchange rate     6.9555       7.2681  

 

Fair Values of Financial Instruments

 

The Company adopted ASC 820 “Fair Value Measurements,” which defines fair value, establishes a three-level valuation hierarchy for disclosures of fair value measurement and enhances disclosures requirements for fair value measures. Current assets and current liabilities qualified as financial instruments and management believes their carrying amounts are a reasonable estimate of fair value because of the short period of time between the origination of such instruments and their expected realization and if applicable, their current interest rate is equivalent to interest rates currently available. The three levels are defined as follow:

 

Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

 

Level 2 — inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

 

Level 3 — inputs to the valuation methodology are unobservable and significant to the fair value.

 

As of the balance sheet date, the estimated fair values of the financial instruments approximated their fair values due to the short-term nature of these instruments. Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates the hierarchy disclosures each year.

 

Cash and Cash Equivalents

 

Cash consists of cash on hand and cash in bank, as well as balances in Douyin and Meituan accounts, which are highly liquid and have original maturities of three months or less and are unrestricted as to withdrawal or use. The Company maintains cash with various financial institutions primarily in mainland China. The Company has not experienced any losses in bank accounts. The balances in Douyin and Meituan represent transaction balances from customers purchasing products through these platforms. Merchants’ income can be withdrawn within 1-3 business days without any restrictions.

 

Short-term investment

 

Short-term investments consist of bank term deposits maturing within one to three months. These deposits are measured at amortized cost, with interest income recognized using the contractual bank rates.

 

  F-8  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Accounts Receivable and allowance for credit losses

 

Accounts receivables are stated at the historical carrying amount net of allowance for expected credit losses.

 

The Company adopted ASU No. 2016-13, “Financial Instruments — Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” on January 1, 2023 using a modified retrospective approach. The Company also adopted this guidance to due from related parties, loans receivable from franchisees, other receivables. To estimate expected credit losses, the Company has identified the relevant risk characteristics of its customers and the related receivables. The Company considers the past collection experience, current economic conditions, future economic conditions (external data and macroeconomic factors), and changes in the Company’s customer collection trends. The allowance for credit losses and corresponding receivables were written off when they are determined to be uncollectible.

 

Inventory

 

Inventories, which are primarily comprised of finished goods for sale, goods shipped to customer and raw materials, are stated at the lower of cost or net realizable value, using the weighted average method and is based on purchase cost. The Company evaluates the need for reserves associated with obsolete, slow-moving and non-salable inventory by reviewing net realizable values on a periodic basis.

 

Loans Receivable

 

Loans receivable is recorded at origination at the fair value less estimates for expected credit losses. Loans receivable is reviewed periodically to determine whether it‘’s carrying value has become impaired. The Company uses credit loss method to estimate the allowance for loans receivables.

 

Property and Equipment

 

Property and equipment are stated at historical cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Property and equipment are depreciated on a straight-line basis over the following periods:

 

Office furniture   5 years
Motor Vehicle   4 years
Office equipment   2.5-5 years
Leasehold improvements   Shorter of the remaining lease terms or estimated useful lives

 

Intangible assets

 

Intangible assets with definite useful lives are amortized over their estimated useful lives to their estimated residual values. Intangible assets mainly represent software at cost, less accumulated amortization on a straight-line basis over an estimated life of ten years.

 

Impairment of long-lived assets other than goodwill

 

Long-lived assets are evaluated for impairment whenever events or changes in circumstances (such as a significant adverse change to market conditions that will impact the future use of the assets) indicate that the carrying amount may not be fully recoverable or that the useful life is shorter than the Company had originally estimated. When these events occur, the Company evaluates the impairment by comparing carrying value of the assets to an estimate of future undiscounted cash flows expected to be generated from the use of the assets and their eventual disposition. If the sum of the expected future undiscounted cash flows is less than the carrying value of the assets, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over the fair value of the assets. Impairment charge recognized for the six months ended April 30, 2026 and 2025 was nil.

 

  F-9  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Related parties

 

The Company adopted ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. According to the standard, financial statements are required to disclose material related-party transactions other than compensation arrangements, expense allowances, or other similar items that occur in the ordinary course of business. A related party is essentially any party that controls or can significantly influence the management or operating policies of the company to the extent that the company may be prevented from fully pursuing its own interests. Related parties include affiliates, investees accounted for by the equity method, trusts for the benefit of employees, principal owners, management, and immediate family members of owners or management. Transactions with related parties must be disclosed even if there is no accounting recognition made for such transactions (e.g., a service is performed without payment).

 

Lease

 

The Company recognizes right-of-use (“ROU”) assets and lease liabilities for its lease commitments with terms greater than one year. Contractual options to extend or terminate lease agreements are reflected in the lease term when they are reasonably certain to be exercised. The initial measurements of new ROU assets and lease liabilities are based on the present value of future lease payments over the lease term as of the commencement date. In determining future lease payments, the Company has elected not to separate lease and non-lease components. As the Company’s lease arrangements do not provide an implicit interest rate, we apply the Company’s incremental borrowing rate based on the information available at the commencement date in determining the present value of future lease payments. Relevant information used in determining the Company’s incremental borrowing rate includes the duration of the lease, transaction currency of the lease, and the Company’s credit risk relative to risk-free market rates. The Company’s ROU assets also include any initial direct costs incurred and exclude lease incentives. The Company’s lease agreements do not contain any significant residual value guarantees or restrictive covenants. All leases of the Company are classified as operating leases, with lease expense being recognized on a straight-line basis.

 

Revenue Recognition

 

In 2014, the FASB issued guidance on revenue recognition (“ASC 606”), with final amendments issued in 2016. The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected. ASC 606 creates a five-step model that requires entities to exercise judgment when considering the terms of contracts, which includes (1) identifying the contracts or agreements with a customer, (2) identifying our performance obligations in the contract or agreement, (3) determining the transaction price, (4) allocating the transaction price to the separate performance obligations, and (5) recognizing revenue as each performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to its clients. The Company has concluded that the new guidance did not require any significant change to its revenue recognition processes.

 

The Company generate revenues from sales of beauty products and devices, and management of beauty salon franchises.

 

Sales of Beauty Products and Devices:

 

The contracts for sales of beauty products and devices are established either through direct transactions or through formal agreements, creating enforceable rights and obligations for both parties. For these sales, the Company recognizes a single performance obligation: the transfer of goods to the customer. There are no additional identifiable promises within these contracts. The Company does not offer price protection but do allow for the return of goods in cases of quality issues, adhering to the standard warranty practices. The Company recorded reserve for sales returns was $nil for the six months ended April 30, 2026, and 2025.

 

  F-10  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

For sales at our owned store locations, revenue is recognized at the point of transfer of control, typically when the customer makes payment and accepts the goods in-store.

 

Regarding online sales via third-party platforms, control is transferred, and revenue is recognized at the point of delivery to the customer, facilitated by express delivery services.

 

Sales and deliveries of beauty products and devices to the franchisees are treated as distinct performance obligations, separate from the franchise agreement. These transactions are not highly dependent on, nor are they integrated with, the franchise services, allowing the franchisee to benefit from the goods independently. Revenue from sales to franchisees is recognized upon the transfer of control of the goods, generally upon delivery. As franchisees take ownership and resell the products at their discretion, these transactions are not considered consignment sales.

 

Management of beauty salon franchises:

 

The Company’s franchise revenues comprise non-refundable initial franchise fees received from franchisees. The initial franchise services, which constitute the Company’s obligation under these agreements, include: (i) granting exclusive operating rights in a specific area, (ii) allowing the use of the “PARK HA” brand, and (iii) providing initial setup services. These setup services encompass assistance with site selection, marketing strategy formulation, and training for franchisee management and beauticians.

 

Following the revenue recognition standard ASC 606, we consider the initial franchise services indistinct from the ongoing rights provided during the franchise agreement term. Consequently, these services are treated as a single performance obligation. Accordingly, initial franchise fees are deferred and recorded as a “Contract Liability.” These fees are recognized over the franchise term as the performance obligation is satisfied, typically spanning one year.

 

The Company offers advertising and renovation subsidies to franchisees, calculated as a percentage of the franchise fee. Since these subsidies are not in exchange for distinct goods or services from franchisees, they are accounted for as a reduction in the transaction price of the franchise fee.

 

The Company also offers short-term loans to franchisees, with terms not exceeding six months. The loan amounts are based on the franchise fee and a fixed ratio. Given the short duration of these loans, as a practical expedient, the Company does not adjust the consideration for the effects of a significant financing component.

 

Contract liability

 

The contract liabilities consist of advances from customers, which relate to unsatisfied performance obligations at the end of each reporting period and consists of cash payments received in advance from customers in sales of beauty products and devices and unearned franchise fee. As of April 30, 2026 and October 31, 2025, the Company’s advances from customer deposit and unearned franchise fee amounted to $194,968 and $194,753, respectively.

 

The Company reports revenues net of applicable sales taxes and related surcharges.

 

  F-11  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Cost of revenues

 

Costs of sales of beauty products and devices consist primarily of materials costs, shipping and handling expenses, inspection costs and related costs, which are directly attributable to products. Write-down of inventories is also recorded in cost of sales, if any.

 

Costs of revenue of beauty salon franchises consist primarily of training costs, promotional material costs and related costs, which are directly attributable to franchises business.

 

Shipping and handling fees incurred to transport goods to customers are paid directly to the logistics company by customers.

 

Selling and marketing expense

 

Sales and marketing expenses consist primarily of salaries & wages expenses to sales and marketing personnel, promotion expenses, depreciation expense of leasehold improvements, rent expense, social insurance, and advertising cost etc. The Company expenses all advertising costs as incurred. Advertising costs were $14,947 and $3,010 for the six months ended April 30, 2026 and 2025, respectively.

 

General and administrative expenses

 

General and administrative expenses consist primarily of legal and other professional service fee, audit fee, salary & wages for employees involved in general corporate functions and those not specifically dedicated to research and development activities, depreciation of fixed assets which are not used in research and development activities, directors’ remuneration, rent, vehicle lease, training fee, conference fee, and other general corporate related expenses.

 

Research and development

 

The Company expenses research and development expenses when incurred as periodic costs. The Company recognized research and development expenses for the six months ended April 30, 2026, and 2025 in the amounts of $138,618 and $26,087, respectively. Research and development expenses primarily comprise of employees’ wages and benefits, outsourced research and development costs, as well as expenditures related to patent fees.

 

Value Added Tax (VAT)

 

In accordance with the relevant tax laws in the PRC, VAT is levied on the invoiced value of sales and is payable by the purchaser. The Company is required to remit the VAT it collects to the tax authority but may deduct the VAT it has paid on eligible purchases. The difference between the amounts collected and paid is presented as VAT recoverable or payable balance on the balance sheet.

 

Income Taxes

 

Income taxes are provided in accordance with ASC No. 740, Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carry-forwards. Deferred tax expense (benefit) results from the net change during the periods of deferred tax assets and liabilities.

 

Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

 

  F-12  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

A tax benefit from an uncertain tax position may be recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities. The determination is based on the technical merits of the position and presumes that the relevant taxing authority that has full knowledge of all relevant information will examine each uncertain tax position. Although the Company believes the estimates are reasonable, no assurance can be given that the final outcome of these matters will not be different than what is reflected in the historical income tax provisions and accruals.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) consists of two components, net income and other comprehensive income. The foreign currency translation gain or loss resulting from translation of the financial statements expressed in RMB to US$ is reported in foreign currency translation loss in the unaudited condensed consolidated statements of operations and comprehensive income.

 

Statutory Reserves

 

Pursuant to the laws applicable to the PRC, PRC entities must make appropriations from after-tax profit to the non-distributable “statutory surplus reserve fund”. Subject to certain cumulative limits, the “statutory surplus reserve fund” requires annual appropriations of 10% of after-tax profit until the aggregated appropriations reach 50% of the registered capital (as determined under accounting principles generally accepted in the PRC (“PRC GAAP”) at each year-end). For foreign-invested enterprises and joint ventures in the PRC, annual appropriations should be made to the “reserve fund”. For foreign-invested enterprises, the annual appropriation for the “reserve fund” cannot be less than 10% of after-tax profits until the aggregated appropriations reach 50% of the registered capital (as determined under PRC GAAP at each year-end). If the Company has accumulated loss from prior periods, the Company is able to use the current period net income after tax to offset the accumulated loss.

 

Earnings (loss) per share

 

Basic earnings (loss) per share is computed by dividing net income (loss) attributable to the holders of ordinary shares by the weighted average number of ordinary shares outstanding during the period. Diluted earnings (loss) per share is calculated by dividing net income (loss) attributable to the holders of ordinary shares as adjusted for the effect of dilutive ordinary share equivalents, if any, by the weighted average number of ordinary shares and dilutive ordinary share equivalents outstanding during the period. For the six months ended April 30, 2026 and 2025, the Company does not have any outstanding ordinary shares equivalents; therefore, a separate computation of diluted earnings (loss) per share is not presented.

 

Commitments and Contingencies

 

The Company follows ASC 450-20, “Loss Contingencies,” to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated. There were no commitments or contingencies as of April 30, 2026 and October 31, 2025.

 

  F-13  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

 

Segment reporting

 

In November 2023, the FASB issued Accounting Standards Update, or ASU 2023-07 – Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements, including additional, more detailed information about a reportable segment’s expenses. The Company adopted ASU 2023-07 for the year ended October 31, 2025, retrospectively to all periods presented in the consolidated financial statement. The adoption of this ASU had no material impact on reportable segments identified and had no effect on the Company’s consolidated balance sheets, results of operations, or cash flows.

 

Based on the criteria established by ASC 280, Segment Reporting, the Company uses the management approach in determining its operating segments. The Company’s chief operating decision maker (“CODM”) is the Chief Executive Officer, who reviews consolidated results when making decisions, allocating resources and assessing performance of the Company. The CODM considers that the Company has two business segments which are comprised of products sales and franchise service. As our long-lived assets are substantially located in the PRC, no geographical segments are presented.

 

The CODM evaluates segment performance and makes resource allocation decisions by regularly reviewing segment net income (loss), which is also reported as consolidated net income (loss) in the consolidated statements of operations and comprehensive income (loss). Segment assets are measured and reported as total consolidated assets on the consolidated balance sheets.

 

Concentration and risks

 

a) Concentration of credit risk

 

Financial instruments that potentially subject the Company to concentration of credit risk are cash and cash equivalents, and accounts receivable arising from its normal business activities. The Company places its cash in what it believes to be credit-worthy financial institutions or trading platforms.

 

The Company conducts credit evaluations of customers, and generally does not require collateral or other security from its customers. The Company establishes an allowance for expected credit losses primarily based upon the factors surrounding the credit risk of specific customers.

 

b) Foreign currency exchange rate risk

 

The functional currency and the reporting currency of the Company are RMB and U.S. dollars, respectively. The Company’s exposure to foreign currency exchange rate risk primarily relates to cash, accounts receivable and accounts payable. Any significant fluctuation of RMB against U.S. dollars may materially and adversely affect the Company’s cash flows, revenues, earnings and financial positions.

 

Recent Accounting Pronouncements

 

Recently issued Accounting Standards Updates (ASUs) by the FASB are not expected to have a significant impact on the Companys consolidated results of operations or financial position. Other accounting standards that have been issued by FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on, or are unrelated to, its consolidated financial condition, results of operations, cash flows or disclosures.

 

Note 3 — Variable interest entity

 

On July 28, 2025, August 11,2025 ,January 22, 2025 and November 27, 2025, Park Ha Jiangsu entered into the Contractual Arrangements with Xinyuexuan, Aimeihui, Xuanyayue and Hefeng. The significant terms of these Contractual Arrangements are summarized in “Note 1 – Nature of business and organization” above. As a result, the Company classifies Xinyuexuan, Aimeihui, Xuanyayue and Hefeng as a VIE which should be consolidated based on the structure as described in Note 1.

 

  F-14  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

Note 3 — Variable interest entity (cont.)

 

A VIE is an entity that has either a total equity investment that is insufficient to permit the entity to finance its activities without additional subordinated financial support, or whose equity investors lack the characteristics of a controlling financial interest, such as through voting rights, right to receive the expected residual returns of the entity or obligation to absorb the expected losses of the entity. The variable interest holder, if any, that has a controlling financial interest in a VIE is deemed to be the primary beneficiary and must consolidate the VIE. Park Ha Jiangsu is deemed to have a controlling financial interest and be the primary beneficiary of Xinyuexuan, Aimeihui, Xuanyayue and Hefeng, because it has both of the following characteristics:

 

  (1) The power to direct activities at Xinyuexuan, Aimeihui, Xuanyayue and Hefeng that most significantly impact such entity’s economic performance, and

 

  (2) The right to receive benefits from Xinyuexuan, Aimeihui, Xuanyayue and Hefeng that could potentially be significant to such entity.

 

Pursuant to the Contractual Arrangements, Park Ha Jiangsu, as the actual capital contributor, is responsible for their operational management and is entitled to all profits generated from these entities as well as bears all losses incurred thereby. The Contractual Arrangements are designed so that Xinyuexuan, Aimeihui, Xuanyayue and Hefeng operates for the benefit of Park Ha Jiangsu and ultimately, the Company.

 

Under the Contractual Arrangements, the Company has the power to direct activities of the VIEs and can have assets transferred out of the VIEs. Therefore, the Company considers that there is no asset in the VIEs that can be used only to settle obligations of the VIEs, except for registered capital and PRC statutory reserves, if any. As the VIEs are incorporated as Individually-Owned Business under the Company Law of the PRC, creditors of the VIEs do not have recourse to the general credit of the Company for any of the liabilities of the VIEs.

 

Accordingly, the accounts of Xinyuexuan, Aimeihui, Xuanyayue and Hefeng are consolidated in the accompanying consolidated financial statements. In addition, its financial positions and results of operations are included in the Company’s interim condensed consolidated financial statements. 

 

The carrying amount of the VIEs’ unaudited Interim consolidated assets and liabilities are as follows:

 

   

April 30,

2026

    October 31,
2025
 
ASSETS            
Current assets            
Cash and cash equivalents     37,222       97,472  
Accounts receivables, net     3,674       2,006  
Amounts due from Group companies     95,891       2,062  
Inventories, net     6,473       3,611  
Other receivables and other current assets     70,171       570  
Total current assets     213,431       105,721  
Non-current Assets                
Property and equipment, net     175,583       99,675  
Operating lease right of use asset, net     42,008       34,508  
Other non-current assets     6,735       1,405  
Total non-current assets     224,326       135,588  
TOTAL ASSETS     437,757       241,309  
                 
LIABILITIES                
Current liabilities                
Amounts due to Group companies     167,185       76,226  
Operating lease liabilities – current     27,504       22,526  
Accruals and other payables     46,871       36,255  
Total current liabilities     241,560       135,007  
Non-current liabilities                
Operating lease liabilities – non-current     8,295       12,901  
Total non-current assets     8,295       12,901  
TOTAL LIABILITIES     249,855       147,908  

  

  F-15  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

Note 3 — Variable interest entity (cont.)

 

The summarized operating results of the VIEs are as follows: 

 

   

Six Months

Ended

April 30,

2026

   

Six Months

Ended

April 30,

2025

 
Revenues, net     353,387      
-
 
Cost of revenues     20,611      
-
 
Gross profit     332,776      
-
 
                 
Operating expenses                
Selling and marketing expenses     206,284      
-
 
General and administrative expenses     37,641      
-
 
Total operating expenses     243,925      
-
 
Operating income     88,851      
-
 
                 
Other income (expense):                
Other income (expense)    
-
     
-
 
Interest income     21      
-
 
Total other income (expenses)     21      
-
 
                 
Net income     88,872      
-
 

 

  F-16  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

Note 3 — Variable interest entity (cont.)

 

Selected Unaudited Interim Condensed Consolidating Financial Schedule 

 

As a holding company with no material operations of its own, substantially all of our business activities are conducted through our subsidiaries and variable interest entities (VIEs) located in the People’s Republic of China (PRC). The following tables present selected condensed consolidated financial data of Park Ha Cayman and its subsidiaries and the VIEs and the WFOE and the primary beneficiary company of the VIEs as of April 30, 2026.

 

The VIEs were effectively established primarily in the second half of 2025 and did not commence operations until after that date. Therefore, the schedule included below presents financial information only for the fiscal year ended October 31, 2025 and the six months ended April 30, 2026 only.

 

SELECTED UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS)

 

For the six month ended,
April 30, 2026
   

The parent
company

Park Ha

   

The WFOE

Park Ha

   

The primary
beneficiary
of the VIEs

Park Ha

          Other           Consolidated  
    Cayman     Investment     Jiangsu     VIEs     entities     Eliminations     Total  
Revenue    
     
      254,136       353,387       677,932       (27,766 )     1,257,689  
Cost of revenue    
      180       47,729       20,611       4,965       (27,766 )     45,719  
Gross profit    
      (180 )     206,407       332,776       672,967      
      1,211,970  
Investments in subsidiaries and the VIEs     (299,263 )    
     
     
     
      299,263      
 
Net income (loss)     (918,282 )     (29,512 )     (261,203 )     88,872       (97,420 )     299,263       (918,282 )
Comprehensive income (loss)     (851,566 )     (29,512 )     (261,182 )     88,872       (101,075 )     302,897       (851,566 )

 

  F-17  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

Note 3 — Variable interest entity (cont.)

 

SELECTED UNAUDITED INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

 

As of April 30, 2026
   

The parent
company

Park Ha

   

The WFOE

Park Ha

   

The primary
beneficiary
of the VIEs

Park Ha

          Other           Consolidated  
    Cayman     Investment     Jiangsu     VIEs     entities     Eliminations     Total  
Cash and cash equivalents     139,306       276       21,784       37,222       429,263      
      627,851  
Short term Investment     3,805,278       1,224,366      
     
     
     
      5,029,644  
Receivable from the VIEs    
     
      37,576      
      92,991       (130,567 )    
 
Intercompany Receivable    
     
      518,097       95,891       2,907,573       (3,521,561 )    
 
Total current assets     3,944,584       1,224,642       717,304       213,431       4,335,171       (3,652,128 )     6,783,004  
Investments in subsidiaries and the VIEs     3,483,557       207,842      
     
      304,659       (3,996,058 )    
 
Total assets     7,428,141       1,432,484       920,295       437,757       4,890,605       (7,648,186 )     7,461,096  
Payable to the VIEs    
     
      2,150      
      57,124       (59,274 )    
 
Intercompany Payable     2,010,851      
      977,402       167,185       324,969       (3,480,407 )    
 
Total liabilities     2,040,851       170       1,249,415       249,855       2,073,196       (3,539,681 )     2,073,806  
Total shareholders’ equity     5,387,290       1,432,314       (329,120 )     187,903       2,817,408       (4,108,505 )     5,387,290  
Total liabilities and shareholders’ equity     7,428,141       1,432,484       920,295       437,757       4,890,605       (7,648,186 )     7,461,096  

 

As of October 31, 2025
   

The parent
company

Park Ha

   

The WFOE

Park Ha

   

The primary
beneficiary
of the VIEs

Park Ha

          Other           Consolidated  
    Cayman     Investment     Jiangsu     VIEs     entities     Eliminations     Total  
Cash and cash equivalents     2,056,270       1,403,036       100,677       97,472       130,223      
      3,787,678  
Receivable from the VIEs    
     
      30,820      
      44,002       (74,822 )    
 
Intercompany Receivable    
     
      486,374       2,062       2,653,362       (3,141,798 )    
 
Total current assets     2,349,603       1,403,036       746,951       105,721       4,113,271       (3,216,620 )     5,501,962  
Investments in subsidiaries and the VIEs     3,716,103      
     
     
     
      (3,716,103 )    
 
Total assets     6,065,706       1,403,036       966,094       241,309       4,494,433       (7,217,962 )     5,952,616  
Payable to the VIEs    
     
      2,062      
      (1,405 )     (657 )    
 
Intercompany Payable     2,010,851      
      918,329       76,226       180,969       (3,186,375 )    
 
Total liabilities     2,070,851       163       1,197,986       147,908       1,727,886       (3,187,033 )     1,957,761  
Total shareholders’ equity     3,994,855       1,402,873       (231,892 )     93,401       2,766,547       (4,030,929 )     3,994,855  
Total liabilities and shareholders’ equity     6,065,706       1,403,036       966,094       241,309       4,494,433       (7,217,962 )     5,952,616  

 

  F-18  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

Note 3 — Variable interest entity (cont.)

 

SELECTED UNAUDITED INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

For the six month ended,
April 30, 2026
   

The parent
company

Park Ha

   

The WFOE

Park Ha

   

The primary
beneficiary
of the VIEs

Park Ha

          Other           Consolidated  
    Cayman     Investment     Jiangsu     VIEs     entities     Eliminations     Total  
Net cash  (used in) provided byoperating activities     (360,964 )     (34,988 )     (195,074 )     79,739       397,560               (113,727 )
Net cash (used in) provided by investing activities     (3,800,000 )     (1,422,901 )     (3,853 )     (143,771 )     (188,144 )     204,011       (5,354,658 )
Net cash provided by (used in) financing activities     2,244,000      
      (7,189 )            
     
      2,236,811  

 

NOTE 4 — ACCOUNTS RECEIVABLES, NET

 

As of April 30, 2026 and October 31, 2025, accounts receivables, net is comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Accounts receivables – Non franchisees     26,001       22,331  
Allowance for expected credit losses     (18,623 )     (17,866 )
Accounts receivables, net – Non-franchisees     7,378       4,465  

 

   

April 30,

2026

   

October 31,

2025

 
Accounts receivables – Franchisees     141,770       378,372  
Allowance for expected credit losses     (132,380 )     (126,993 )
Accounts receivables, net – Franchisees     9,390       251,379  

 

 

  F-19  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 4 — ACCOUNTS RECEIVABLES, NET (cont.)

 

In accordance with contractual agreements, the Company has the power to direct the activities of the VIEs and can have assets transferred out of the VIEs. Therefore, the Company considers that there are no assets in the respective VIEs that can be used only to settle obligations of the respective VIEs as of April 30, 2026 and October 31, 2025. As the respective VIEs are incorporated as individual business under the PRC Company Law, creditors do not have recourse to the general credit of the Company for the liabilities of the respective VIEs.

 

The following is a summary of the activity in the allowance for expected credit losses:

 

   

April 30,

2026

   

October 31,

2025

 
Balance at beginning of period – Non-franchisees     17,866       157,769  
Provision    
     
 
Reversal    
      (50,091 )
Written-off    
      (87,923 )
Effect of translation adjustment     757       (1,889 )
Balance at end of period – Non-franchisees     18,623       17,866  

 

   

April 30,

2026

   

October 31,

2025

 
Balance at beginning of period – Franchisees     126,993       74,082  
Provision    
      52,180  
Reversal    
     
 
Effect of translation adjustment     5,387       731  
Balance at end of period – Franchisees     132,380       126,993  

 

NOTE 5 — INVENTORY, NET

 

As of April 30, 2026 and October 31, 2025, inventory comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Raw materials     28,148       13,254  
Finished goods     87,168       74,491  
Allowance for Inventory     (11,270 )     (12,531 )
Inventories, net     104,046       75,214  

 

Inventory write-down expense was $134 and $4,734 for the six months ended April 30, 2026 and 2025, respectively.

 

  F-20  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 6 — LOANS RECEIVABLE FROM FRANCHISEES, NET

 

Loans receivables from franchisees consist of non-interest-bearing advances provided by the Company to its franchisees to purchase inventory, equipment; or for use as working capital. The maturity date of the loan is 180 days from the date of disbursement of funds.

 

As of April 30, 2026 and October 31, 2025, loan receivables from franchisees, net comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Loan receivables from franchisees     1,420,034       1,254,057  
Allowance for expected credit losses     (534,173 )     (232,876 )
Loan receivables from franchisees, net     885,861       1,021,181  

 

The following is a summary of the activity in the allowance for expected credit losses:

 

   

April 30,

2026

   

October 31,

2025

 
Balance at beginning of period     232,876       55,520  
Provision     286,049       183,501  
Written-off    
      (8,571 )
Effect of translation adjustment     15,248       2,426  
Balance at end of period     534,173       232,876  

 

The following is a summary of the movement of the loan:

 

   

April 30,

2026

   

October 31,

2025

 
Balance at beginning of period     1,254,057       801,512  
Loans lend to franchisees     573,650       1,103,211  
Repayment from franchisees     (462,945 )     (656,937 )
Effect of translation adjustment     55,272       6,271  
Balance at end of period     1,420,034       1,254,057  

 

The amount of loans that are past due as of April 30,2026 and October 31, 2025 were $835,616 and $947,042 respectively. As of the reporting date, the amount of loans that are past due is $826,095.

 

  F-21  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 6 — LOANS RECEIVABLE FROM FRANCHISEES, NET (cont.)

 

As of April 30, 2026 and October 31, 2025, loans receivable from franchisees, net comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Gao Wenjing     54,926       52,691  
Wang Shimei     54,926       52,691  
Zeng Yongjian     48,335       46,369  
Song Mingfang     58,588       52,691  
Wang Zhiya    
      52,691  
Yu Yang     58,588       108,896  
Yan Tianxiang     9,521      
 
Wang Xuefeng     190,412       182,664  
Zheng Yanhai     9,521       9,133  
Chen Yu    
      9,133  
Zhang Ying    
      9,133  
Wang Hongli    
      9,133  
Ge Xiaoqing     117,177      
 
Sheng Xidong     9,521      
 
Zhou Guixiang     68,109      
 
Wang Jia     9,521      
 
Meng Hao     58,588       52,691  
Sun Zhongyao     9,521      
 
Wu Yinghan     190,412       182,664  
Liu Yuping     190,412       182,664  
Xiao Yang     19,041       18,266  
Shen Yue     9,521       9,133  
Zhao Zhe     9,521       9,134  
Shen Huaimei     58,588       108,896  
Sun Xuqiang     68,109      
 
 
Zhu Hongjun     58,588      
 
 
Wang Jingfeng     58,588      
 
 
Tang Sumei    
      52,692  
Li Ruonan    
      52,692  
      1,420,034       1,254,057  
Less: Allowance for expected credit loss     (534,173 )     (232,876 )
Loan receivables from franchisees, net     885,861       1,021,181  

 

  F-22  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 7 — OTHER RECEIVABLES AND OTHER CURRENT ASSETS, net

 

As of April 30, 2026 and October 31, 2025, other receivables and other current assets comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Other receivables     27,132       25,765  
Prepaid expenses     91,123       337,863  
Total     118,255       363,628  
Allowance for expected credit loss     (11,468 )     (11,002 )
Other receivables and other current assets, net     106,787       352,626  

 

NOTE 8 — PROPERTY & EQUIPMENT, NET

 

As of April 30, 2026 and October 31, 2025, property and equipment, net comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
At Cost:            
Office furniture     9,232       8,856  
Motor vehicle     153,852       147,591  
Office equipment     23,334       13,189  
Leasehold improvements     496,627       265,653  
 Total, Cost     683,045       435,289  
Accumulated depreciation     (385,610 )     (277,290 )
Total, net     297,435       157,999  

 

Depreciation expenses were $94,779 and $15,026 for the six months ended April 30, 2026 and 2025, respectively.

 

NOTE 9 — INTANGIBLE ASSETS, NET

 

As of April 30, 2026 and October 31, 2025, intangible assets, net comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
At Cost:            
Trademark     264       253  
Software     10,253       9,836  
                 
Accumulated depreciation     (4,109 )     (3,450 )
Total, net     6,408       6,639  

 

Amortization expenses were $503 and $482 for the six months ended April 30, 2026 and 2025, respectively.

 

    For the years ending October 31,  
    2026*     2027     2028     2029     2030     thereafter  
Amortization expenses     513       1026       1026       1026       1026       1,791  

 

 

* For the six months ending October 31, 2026

 

  F-23  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 10 — OTHER NON-CURRENT ASSETS

 

As of April 30, 2026 and October 31, 2025, other non-current assets comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Lease deposits     33,454       22,416  
Deferred Tax Asset     159,521       83,357  
Total     192,975       105,773  

 

NOTE 11 — TAXES PAYABLE

 

As of April 30, 2026 and October 31, 2025, taxes payable comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Enterprise income tax payable     1,114,087       1,010,451  
Value-added tax, net     356,777       327,124  
City maintenance and construction tax     22,904       21,331  
Additional education fees     9,965       9,286  
Other taxes     8,035       7,296  
Total     1,511,768       1,375,488  

 

NOTE 12 — CONTRACT LIABILITIES

 

For service contracts where the performance obligation is not completed, contract liabilities were recorded for any payments received in advance of the performance obligation. The payments received in advance will not be refunded and will be amortized in future when met performance obligations.

 

As of April 30, 2026 and October 31, 2025, contract liabilities is comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Unearned franchise fee     194,968       194,753  
Customer advance for beauty products    
     
 
Total     194,968       194,753  

 

The unearned franchise fee of $194,968 is to be recognized to revenue within one year from April 30, 2026.

 

  F-24  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 12 — CONTRACT LIABILITIES (cont.)

 

As of April 30, 2026 and October 31, 2025, unearned franchise fee comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Yan Tianxiang     2,448      
 
Song Mingfang     13,463      
 
Yu Yang     20,527       58,015  
Sheng Xidong     2,448      
 
Zhou Guixiang     14,747      
 
 
Wang Jia     2,448      
 
Ge Xiaoqing     20,526      
 
Meng Hao     6,882      
 
Wang Hongli    
      2,850  
Zhang Ying    
      2,964  
Sun Zhongyao     2,448      
 
Sun Xuqiang     15,911      
 
Zheng Tinghai     5,498       12,242  
Zhu Hongjun     12,360      
 
Tang Sumei    
      26,947  
Jin Huazhong    
      34,935  
Shen Huaimei     61,799       56,800  
Wang Jingfeng     13,463      
 
Total     194,968       194,753  

 

NOTE 13 — RELATED PARTY TRANSACTIONS

 

The Company had transactions with the following related parties:

 

Name of Related Party   Nature of Relationship
Guozhen Liu   Limited partner of Changxin International Limited Partnership, executive director and legal representative of Park Ha Shanghai, supervisor of XinZhan, parent of Xiaoqiu Zhang
Fujun Yu   Executive director, legal representative of Park Ha Jiangsu, supervisor of Park Ha Shanghai
Hengquan Zhang   Supervisor of Park Ha Jiangsu, parent of Xiaoqiu Zhang
Xiaoqiu Zhang   CEO, Chairperson of the board of directors, controlling shareholder of Park Ha Cayman
Li Wang   COO, Supervisor of Park Ha Investment

 

Due from related party

 

The Company made advances to Ms. Xiaoqiu Zhang for working capital to be paid on behalf of the Company. The balance due from Ms. Xiaoqiu Zhang was $37 and $35 as of April 30, 2026 and October 31, 2025, respectively.

 

The Company made advances to Ms. Li Wang for working capital to be paid on behalf of the Company. The balance due from Ms. Li Wang was $732 and $nil as of April 30, 2025 and October 31, 2025, respectively.

 

Due to related party

 

The Company received advances from Ms. Li Wang as working capital. The balance due to Ms. Li Wang was $nil and $7,026 as of April 30, 2026 and October 31, 2025, respectively.

 

The amounts due from related party and due to related party above are non-interest bearing, without maturity and due on demand.

 

  F-25  

 

  

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 14 — LEASES

 

As of April 30, 2026, the Company has entered into several operating leases for its self-operated stores, dormitories and offices. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The Company accounts for the lease and non-lease components of its leases as a single lease component. Lease expense is recognized on a straight-line basis over the lease term.

 

Operating lease right-of-use assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The discount rate used to calculate present value is incremental borrowing rate or, if available, the rate implicit in the lease.

 

The components of lease expense and supplemental cash flow information related to leases for the period are as follows:

 

    For the Six Months End  
    April 30,  
    2026     2025  
Lease Cost            
Operating lease cost   $ 52,027     $ 14,098  
                 
Other Information                
Cash paid for amounts included in the measurement of lease liabilities   $ 46,988     $ 13,422  

 

As of April 30, 2026 and October 31, 2025, the weighted average lease term and discount rate are as follows:

 

   

April 30,

2026

   

October 31,

2025

 
Weighted average remaining lease term – operating leases (in years)     2.05       2.47  
Average discount rate – operating lease     3.21 %     3.25 %

 

As of April 30, 2026 and October 31, 2025, the supplemental balance sheet information related to leases are as follows:

 

   

April 30,

2026

   

October 31,

2025

 
Operating leases            
Right-of-use assets   $ 181,274     $ 180,243  
                 
Operating lease liabilities, current   $ 128,432     $ 104,254  
Operating lease liabilities, non-current     57,899     $ 75,915  
Total operating lease liabilities   $ 186,331     $ 180,169  

  

The undiscounted future minimum lease payment schedule as follows:

 

For the years ending April 30,      
Due and unpaid for 2025     12,304  
Remainder of 2026     74,352  
2027     76,837  
2028     28,308  
Total undiscounted lease payments     191,801  
Less imputed interest     (5,470 )
Total lease liabilities     186,331  

 

  F-26  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 15 — SHAREHOLDERS’ EQUITY

 

The Company was incorporated in the Cayman Islands in October 2022 under the Cayman Islands Companies Act as an exempted company with limited liability.

 

For the year ended October 31, 2022, the Company issued 5,000,000 shares to certain founding shareholders in exchange for US$500 based on the par value. On June 29, 2024, our shareholders approved a share split of our outstanding Ordinary Shares at a ratio of 1:5. The Company has retroactively restated all share data for all of the periods presented pursuant to ASC 260 to reflect the share split, resulting in 25,000,000 Ordinary Shares issued and outstanding after the share split.

 

On December 26, 2024, the Company completed initial public offering, issued and sold 1,200,000 Ordinary Shares, at $4.00 per share for $4.80 million. The net proceeds of $3.89 million after deducting underwriting discounts and the offering expenses payable was received by the Company.

 

On January 24, 2025, the Company issued and sold 174,403 shares to an over-allotment arrangement, at $4.00 per share for $0.70 million. The net proceeds of 0.38million after deducting underwriting discounts and the offering expenses payable was received by the Company.

 

On February 28, 2025, the Board of Directors resolved and approved: the company adopt the 2025 Equity Incentive Plan, under which the total number of authorized and issuable shares of the company’s common stock (with a par value of $0.00002 per share) shall be 3,000,000 shares. On March 5, 2025, the company entered into five grant agreements with the respective grantees, specifying the grant date as March 5, 2025, with the vesting arrangement being immediately exercisable. The company recognized share-based compensation included in administrative expenses of $ 19,950,000 for the year ended October 31, 2025, calculated based on the fair value price of $ 6.65 per share on the grant date of March 5, 2025 multiplied by 3,000,000 shares.

 

On July 7, 2025, the Board of Directors resolved and approved: The Company intends to adopt the 2025 Equity Incentive Plan, under which the total number of authorized and issuable shares of the Company’s common stock (with a par value of $0.00002 per share) shall be 4,500,000 shares. On July 14, 2025, the Company entered into four grant agreements with the respective grantees, specifying the grant date as July 14, 2025, with the vesting arrangement being immediately exercisable. The company recognized share-based compensation included in administrative expenses of $ 4,120,200 for the year ended October 31, 2025, calculated based on the fair value price of $0.9156 per share on the grant date of July 14,2025 multiplied by 4,500,000 shares.

 

On October 3, 2025, at the 2025 annual general meeting of shareholders (the “AGM”) of the Company, the shareholders of the Company passed resolutions to increase the Company’s authorized share capital and re-classify and re-designate the Company’s authorized share capital. As a result, immediately following the AGM, the Company’s authorized share capital was increased, and re-classified and re-designated from US$50,000 divided into 2,500,000,000 Ordinary Shares of par value US$0.00002 each to US$300,000 divided into 12,000,000,000 Class A Ordinary Shares of par value US$0.00002 each, with each Class A Ordinary Share entitled to one vote, and 3,000,000,000 Class B Ordinary Shares of par value US$0.00002 each, with each Class B Ordinary Share entitled to 20 votes. The Company has retroactively restated all share data for all of the periods presented pursuant to ASC 260 to reflect the share reorganization.

 

  F-27  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 15 — SHAREHOLDERS’ EQUITY (cont.)

 

On December 26, 2025, the Company held an extraordinary meeting of shareholders, during which the shareholders approved a proposal to effect a reverse stock split (the “Reverse Split”). The Board of Directors subsequently approved the Reverse Split and determined the exact ratio to be 1-for-50 on January 29, 2026. The Reverse Split became effective on February 20, 2026, and the Class A Ordinary Shares began trading on a post-Reverse Split basis on the Nasdaq Capital Market when the market opened on February 23, 2026, under the same symbol “BYAH.”

 

In connection with the Reverse Split, each 50 pre-split Class A Ordinary Shares outstanding were automatically combined and converted into one issued and outstanding Class A Ordinary Share without any action on the part of the shareholders. The Company did not issue fractional shares in connection with the Reverse Split. Instead, any fractional share interest that would otherwise have resulted from the Reverse Split was rounded up to the nearest whole share. To effect this rounding-up, an aggregate of 35 shares were issued on February 20, 2026, to settle fractional entitlements at the company level. Subsequently, an additional aggregate of 18,360 shares were issued on February 27, 2026, to complete the rounding-up of fractional shares at the individual shareholder level. The rounding-up of fractional shares did not result in any material change to the shareholders’ proportionate ownership interest in the Company.

 

All share and per share amounts disclosed in this report, including earnings per share calculations, have been retroactively restated for all periods presented pursuant to ASC 260 to reflect the Reverse Split. The par value of the Class A Ordinary Shares was also adjusted accordingly from US$0.00002 to US$0.001 per share.

 

On January 28, 2026, the Company completed a public offering, issued and sold 21,875,000 Ordinary Shares, of which 21,875,000 shares related to the public offering, at $0.112 per share for $2.45 million. The net proceeds of $2.244 million after deducting underwriting discounts and the offering expenses payable was received by the Company. The Company also registering 196,875,000 Class A Ordinary Shares underlying the Warrants (the “Warrant Shares”) pursuant to a zero-exercise price option. Each Warrant will have an initial exercise price of $0.112 per Class A Ordinary Share and will be exercisable beginning on the date of the issuance date and ending on the one-year anniversary of the issuance date. As the public offering was completed prior to the effective date of the 1-for-50 reverse stock split on February 20, 2026, the 21,875,000 shares issued in the offering have been retroactively adjusted to reflect the Reverse Split. On a post-split basis, this amount equates to 437,500 Class A Ordinary Shares.The Warrant Shares are also subject to proportional adjustment in connection with the Reverse Split.

 

On January 27, 2026, one holder exercised its 36,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 36,000 Class A Ordinary Shares on January 30, 2026.

 

On February 3, 2026, one holder exercised its 32,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 32,000 Class A Ordinary Shares on February 4, 2026.

 

On February 4, 2026, eleven holders exercised an aggregate of 900,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 900,000 Class A Ordinary Shares on February 4, 2026.

 

On February 5, 2026, one holder exercised its 12,379 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 12,379 Class A Ordinary Shares on February 5, 2026.

 

On February 23, 2026, eleven holders exercised an aggregate of 1,125,121 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 1,125,121 Class A Ordinary Shares on February 23, 2026.

 

 

  F-28  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 15 — SHAREHOLDERS’ EQUITY (cont.)

 

On March 9, 2026, nine holders exercised an aggregate of 1,656,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 1,656,000 Class A Ordinary Shares on March 9, 2026.

 

On April 21, 2026, two holders exercised an aggregate of 30,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 30,000 Class A Ordinary Shares on April 21, 2026.

 

As of April 30, 2026, there were 4,543,884 Class A ordinary shares and 381,000 Class B ordinary shares issued and outstanding.

 

NOTE 16 — RESTRICTED NET ASSETS

 

As a result of the PRC laws and regulations and the requirement that distributions by PRC entities can only be paid out of distributable profits computed in accordance with PRC GAAP, the PRC entities are restricted from transferring a portion of their net assets to the Company. Amounts restricted include paid-in capital, additional paid-in capital, and the statutory reserves of the Company’s PRC subsidiaries.

 

    As of  
   

April 30,

2026

   

October 31,

2025

 
Paid-in capital    
     
 
Additional paid in capital     2,561,211       2,561,211  
Statutory reserve     217,264       217,264  
Total     2,778,475       2,778,475  

 

NOTE 17 — SEGMENTS AND GEOGRAPHIC INFORMATION

 

The Company believes that it operates in two business segments which comprised of products sales and franchise service; and it operates in one geographical location China. The Company disaggregates its revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

 

Summarized financial information for the two reportable segments is as follows:

 

    Six Months Ended April 30, 2026  
    Product Sales     Franchise fees     Consolidated  
Revenues, net     716,105       541,584       1,257,689  
Cost of revenues     44,704       1,015       45,719  
Gross profit     671,401       540,569       1,211,970  
Depreciation and amortization     94,757       525       95,282  
Other expense (income), net     1,230,575       815,615       2,046,190  
Income tax expenses (benefits)     222       (11,442 )     (11,220 )
Net (Loss) Income     (654,153 )     (264,129 )     (918,282 )

 

  F-29  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 17 — SEGMENTS AND GEOGRAPHIC INFORMATION (cont.)

 

    Six Months Ended April 30, 2025  
    Product Sales     Franchise fees     Consolidated  
Revenues, net     404,438       834,759       1,239,197  
Cost of revenues     47,882       10,618       58,500  
Gross profit     356,556       824,141       1,180,697  
Depreciation and amortization     15,508               15,508  
Other expense (income), net     7,112,270       13,709,967       20,822,237  
Income tax expenses (benefits)     1,262       177,684       178,946  
Net (Loss) Income     (6,772,484 )     (13,063,510 )     (19,835,994 )

 

Summarized financial information for revenues, costs and profits is as follows

 

Sales revenues comprised of the following:

 

    Six Months Ended  
    April 30, 2026     April 30, 2025  
Products sales – Non-franchisees     600,022       48 %     208,701       17 %
Product Sales – Franchisees     116,083       9 %     195,737       16 %
Franchise fees     541,584       43 %     834,759       67 %
Total     1,257,689       100 %     1,239,197       100 %

 

Direct costs comprised of the following:

 

    Six Months Ended  
    April 30, 2026     April 30, 2025  
Products sales – Non-franchisees     28,077       62 %     10,316       18 %
Product Sales – Franchisees     16,627       36 %     37,566       64 %
Franchise fees     1,015       2 %     10,618       18 %
Total     45,719       100 %     58,500       100 %

 

Gross profit comprised of the following:

 

    Six Months Ended  
    April 30, 2026     April 30, 2025  
Products sales – Non-franchisees     571,945       47 %     198,385       17 %
Product Sales – Franchisees     99,456       8 %     158,171       13 %
Franchise fees     540,569       45 %     824,141       70 %
Total     1,211,970       100 %     1,180,697       100 %

 

  F-30  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 18 — CONCENTRATION RISKS

 

Concentration of credit risk

 

Cash deposits with banks are held in financial institutions in China, which deposits are not federally insured. Accordingly, the Company has a concentration of credit risk related to the uninsured part of bank deposits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk.

 

Concentration of customers and suppliers

 

The Company has a concentration risk related to suppliers and customers. Failure to maintain existing relationships with the suppliers or customers to establish new relationships in the future could negatively affect the Company’s ability to obtain goods sold to customers in a price advantage and timely manner. If the Company is unable to obtain ample supply of goods from existing suppliers or alternative sources of supply, the Company may be unable to satisfy the orders from its customers, which could materially and adversely affect revenues.

 

For the six months ended of April 30,2026, the company’s customers are relatively scattered, with no single customer accounting for more than 10% of total revenue.

 

The customers that accounted for 10% or more of the Company’s accounts receivable comprised of the following:

 

   

April 30,

2026

   

October 31,

2025

 
Percentage of the Company’s accounts receivable            
Customer D     11 %     4 %
Customer J     50 %     28 %
Customer L    
%     11 %
Customer K     28 %     15 %

 

The suppliers that accounted for 10% or more of the Company’s purchases comprised of the following:

 

    For the Six Months Ended  
   

April 30,

2026

   

April 30,

2025

 
Percentage of the Company’s purchases            
Supplier A     8 %     12 %
Supplier B     11 %     12 %
Supplier C     9 %     13 %
Supplier D    
%    
%
Supplier E     6 %     14 %
Supplier F     18 %    
%
Supplier I     7 %     11 %
Supplier J     5 %     11 %

 

  F-31  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 18 — CONCENTRATION RISKS (cont.)

 

The suppliers that accounted for 10% or more of the Company’s account payables comprised of the following:

 

    April 30,
 2026
    October 31,
2025
 
Percentage of the Company’s accounts payable            
Supplier E     11 %    
%
Supplier G     56 %     81 %
Supplier H     16 %     19 %
Supplier J     14 %    
%

 

NOTE 19 — INCOME TAX

 

Cayman Islands

 

Under the current laws of the Cayman Islands, entities are not subject to tax on income or capital gain. In addition, payments of dividends by the Company to their shareholders are not subject to withholding tax in the Cayman Islands.

 

Hong Kong

 

Park Ha Biological Technology (HK) Co., Ltd. is incorporated in Hong Kong and is subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate for the first HKD$2 million of assessable profits is 8.25% and assessable profits above HKD$2 million will continue to be subject to the rate of 16.5% for corporations in Hong Kong, effective from the year of assessment 2018/2019. Park Ha Biological Technology (HK) Co., Ltd. did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Under Hong Kong tax laws, Park Ha Biological Technology (HK) Co., Ltd.is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends for the six months ended April 30, 2026 and April 30, 2025.

 

China, PRC

 

The Company in general is subject to profits tax rate at 25% for income generated for its operation in China and net operating losses can be carried forward for no longer than five years starting from the year subsequent to the year in which the loss was incurred.

 

In accordance with the implementation rules of EIT Laws, a qualified High and New Technology Enterprise (HNTE) is eligible for a preferential tax rate of 15%. The HNTE certificate is effective for a period of three years. An entity could re-apply for the HNTE certificate when the prior certificate expires. Park Ha Jiangsu obtained its HNTE certificate on November 6, 2024. Therefore, Park Ha Jiangsu is eligible to enjoy a preferential tax rate of 15% from 2024 to 2026 to the extent it has taxable income under the EIT Law.

 

Announcement No. 12 [2023] of the Ministry of Finance and the State Taxation Administration stipulates that the preferential corporate income tax (CIT) policy for small and low-profit enterprises (SLPEs) reducing taxable income by 25% and applying a 20% tax rate shall be extended until December 31, 2027.Wuxi Muchen and Wuxi Mufeng and ParkHa Investment , with annual taxable income not exceeding RMB 1 million for the year ended October 31, 2025, qualify as SLPEs. As such, 25% of their taxable income is subject to CIT at the reduced rate of 20%.

 

Ai Meihui obtained the “Review Approval Notification for Application and Adjustment of Fixed Amount for Periodic Fixed-Amount Taxpayers” issued by the State Taxation Administration, Jiangsu Wuxi Economic Development Zone Tax Bureau on August 30, 2025, indicating that the application for “Periodic Fixed-Amount Taxpayer Application and Adjustment of Fixed Amount” submitted by Ai Meihui on August 22, 2025, has been approved. Upon review, Ai Meihuis account shall implement a monthly taxable amount of 0.0 yuan from August 1, 2025, to December 31, 2025. As of April 30, 2026, the taxable amount assessed by the tax authority under the periodic fixed-amount collection method is nil

 

  F-32  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 19 — INCOME TAX (cont.)

 

Xinyuexuan obtained the “Review Approval Notification for Application and Adjustment of Fixed Amount for Periodic Fixed-Amount Taxpayers” issued by the State Taxation Administration, Jiangsu Wuxi Economic Development Zone Tax Bureau on August 19, 2025, indicating that the application for “Periodic Fixed-Amount Taxpayer Application and Adjustment of Fixed Amount” submitted by Xinyuexuan on August 11, 2025, has been approved. Upon review, Xinyuexuans account shall implement a monthly taxable amount of zero yuan from July 1, 2025, to December 31, 2025. As of April 30, 2026, the taxable amount assessed by the tax authority under the periodic fixed-amount collection method is nil

 

Hefeng received a “Reminder of Approval for Periodic Fixed-Amount Taxpayer’s Application for Assessment and Adjustment of Fixed Quota” issued by the Tax Service Office of Wuxi Economic Development Zone of the State Administration of Taxation on August 19, 2025. The application for “Periodic Fixed-Amount Taxpayer’s Application for Assessment and Adjustment of Fixed Quota” filed by Hefeng on January 5, 2026, has been approved. As a result, Hefeng is subject to a monthly taxable amount of RMB 0.00 for the period from January 1, 2026 to December 31, 2026, as assessed by the tax authority.

 

Income taxes in the PRC are consist of:

 

    For the Six Months Ended  
    April 30,  
    2026     2025  
Current income tax expense     60,070       180,939  
Deferred income tax benefit     (71,290 )     (1,993 )
Total income tax expense     (11,220 )     178,946  

 

The net taxable income before income taxes and its provision for income taxes comprised of the following:

 

    For the Six Months Ended  
    April 30,  
    2026     2025  
Loss attributed to China     (929,502 )     (19,657,048 )
PRC statutory tax rate     25 %     25 %
Income tax expense at PRC statutory income tax rate     (232,375 )     (4,914,262 )
Effect of different tax jurisdiction     154,755      
 
Tax effect of preferential tax treatments     18,378       5,059,645  
Research and development credit     (22,806 )     (3,913 )
Non-deductible expenses     2,454       1,862  
Change in valuation allowance     68,374       35,614  
Tax (benefit) expense, net     (11,220 )     178,946  

 

  F-33  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 19 — INCOME TAX (cont.)

 

As of April 30, 2026 and October 31, 2025 deferred tax assets consist of the following:

 

    As of  
   

April 30,

2026

   

October 31,

2025

 
Net operating losses carried forward in the PRC     252,379       138,115  
Allowance of expected credit loss     157,914       81,598  
Allowance for inventory     1,607       1,759  
Total     411,900       221,472  
Less: Valuation allowance     (252,379 )     (138,115 )
Deferred tax assets, net     159,521       83,357  

 

As of April 30, 2026 and october 31, 2025, the Companys PRC entities had net operating loss carryforwards of approximately $1.36 million and $1.18 million, respectively which will start to expire from 2026. The Company reviews deferred tax assets for a valuation allowance based upon whether it is more likely than not that the deferred tax asset will not be fully realized. As of April 30, 2026 and October 31, 2025, full valuation allowance is provided against the deferred tax assets related to the Companys net operating loss carryforwards based upon managements assessment as to their realization.

 

Note 20 — Commitments and contingencies

 

Variable interest entity structure

 

In the opinion of management, (i) the corporate structure of the Company is in compliance with existing PRC laws and regulations; (ii) the Contractual Arrangements are valid and binding, and do not result in any violation of PRC laws or regulations currently in effect; and (iii) the business operations of Park Ha Jiangsu and the VIEs are in compliance with existing PRC laws and regulations in all material respects.

 

However, there are substantial uncertainties regarding the interpretation and application of current and future PRC laws and regulations. Accordingly, the Company cannot be assured that PRC regulatory authorities will not ultimately take a contrary view to the foregoing opinion of its management. If the current corporate structure of the Company or the Contractual Arrangements is found to be in violation of any existing or future PRC laws and regulations, the Company may be required to restructure its corporate structure and operations in the PRC to comply with changing and new PRC laws and regulations. In the opinion of management, the likelihood of loss in respect of the Company’s current corporate structure or the Contractual Arrangements is remote based on current facts and circumstances.

 

NOTE 21 — SUBSEQUENT EVENTS

 

On June 15, 2026, the Company filed a registration statement for an offering and entered into a Securities Purchase Agreement with certain purchasers, pursuant to which the Company agreed to sell an aggregate of 1,133,332 Class A Ordinary Shares at a public offering price of $1.50 per share, and pre-funded warrants to purchase up to 200,000 Class A Ordinary Shares at a price of $1.49999 per pre-funded warrant (representing the per-share public offering price less an exercise price of $0.00001 per share). The pre-funded warrants are immediately exercisable, subject to a beneficial ownership limitation of 4.99% (or 9.99% at the holder’s election prior to issuance), and will remain exercisable until exercised in full. The Company’s Class A Ordinary Shares are listed on Nasdaq under the symbol “BYAH,” with the last reported sale price of $1.05 per share on June 11, 2026. Each Class A Ordinary Share carries one vote, while each Class B Ordinary Share carries 20 votes and is convertible into one Class A Ordinary Share; Class A Ordinary Shares are not convertible into Class B Ordinary Shares under any circumstances. In this offering, the Company issued an aggregate of 1,333,332 shares (including shares underlying the pre-funded warrants).The net proceeds of $1.74 million after deducting underwriting discounts and the offering expenses payable was received by the Company.

 

On June 19, 2026, two holders exercised an aggregate of 53,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 53,000  Class A Ordinary Shares on June 19, 2026.

 

On July 2, 2026, two holders exercised an aggregate of 53,000 Warrant Shares through an alternative cashless exercise option, and the Company issued a total of 53,000  Class A Ordinary Shares on July 2, 2026.

 

  F-34  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 21 — SUBSEQUENT EVENTS (cont.)

 

On July 13, 2026, at the 2026 extraordinary general meeting of shareholders (the “EGM”) of the Company, the shareholders of the Company passed resolutions to (i) The authorised share capital of the Company is increased from US$3,000,000.00 divided into 3,000,000,000 ordinary shares of par value US$0.001 each, comprising 2,400,000,000 Class A Ordinary Shares and 600,000,000 Class B Ordinary Shares, to US$300,000,000 by creating additional 297,000,000,000 ordinary shares of par value US$ 0.001 each to rank pari passu in all respects with the existing shares in the capital of the Company such that the Company is authorised to issue 300,000,000,000 ordinary shares of par value US$0.001 each, comprising 240,000,000,000 Class A Ordinary Shares and 60,000,000,000 Class B Ordinary Share; (ii)The voting rights attaching to each Class B Ordinary Share are increased from 20 (twenty) votes to 100 (one hundred) votes for each Class B Ordinary Share of which he is the holder;(iii)The Board is hereby authorised, in its sole discretion, to effect one or more consolidations of all of the Company’s authorised, issued and outstanding Class A Ordinary Shares and Class B Ordinary Shares at any time during the three (3)-year period following the date of the Extraordinary General Meeting, with the exact consolidation ratio and effective time to be determined by the Board in its sole discretion, provided that the aggregate consolidation ratio resulting from any and all such share consolidations shall not be less than 2-for-1 nor greater than 5,000-for-1, and that the consolidated shares shall have the same rights and be subject to the same restrictions (other than any adjustment to par value) as the corresponding shares immediately prior to such share consolidation under the Company’s then effective Amended and Restated Memorandum and Articles of Association; and (iiii)The Board is hereby authorised, in its sole discretion, to effect one or more subdivisions of all of the Company’s authorised, issued and outstanding Class A Ordinary Shares and Class B Ordinary Shares at any time during the three (3)-year period following the date of the Extraordinary General Meeting, with the exact subdivision ratio and effective time to be determined by the Board in its sole discretion, provided that the aggregate subdivision ratio resulting from any and all such share subdivisions shall not be less than 2-for-1 nor greater than 100-for-1, and that the subdivided shares shall have the same rights and be subject to the same restrictions (other than any adjustment to par value) as the corresponding shares immediately prior to such share subdivision under the Company’s then effective Amended and Restated Memorandum and Articles of Association.

 

Board Resolution Dated May 8, 2026, the registered operators of Xinyuexuan Beauty Salon, Aimeihui Beauty Center, and Hefeng Beauty Store shall cease all operational activities and transfer all related business assets to the entity designated by Jiangsu Park Ha, while simultaneously settling all outstanding payables through the offset of the transfer consideration, and canceling the Company’s VIE structure.

 

On May 29, 2026, the Company incorporated Wuxi Ninglan Biotechnology Co., Ltd., a limited liability company100% owned by Jiangsu Park.

 

On May 29, 2026, the Company incorporated Wuxi Youlan Biotechnology Co., Ltd.,a limited liability company100% owned by Jiangsu Park.

 

On June 1, 2026, the Company incorporated Wuxi Boran Biotechnology Co., Ltd., a limited liability company100% owned by Jiangsu Park.

 

On June 8, 2026, the Company incorporated Wuxi Manhui Biotechnology Co., Ltd., a limited liability company100% owned by Jiangsu Park.

 

On June 8, 2026, the Company incorporated Wuxi Aimeihui Biotechnology Co., Ltd., a limited liability company100% owned by Jiangsu Park.

 

On July 15, 2026, the Company incorporated Wuxi Huiyan Biotechnology Co., Ltd., a limited liability company100% owned by Jiangsu Park.

 

The Company has evaluated subsequent events from April 30, 2026 and through the date of issuance of the consolidated financial statements which is July 24, 2026 and did not identify any subsequent events except disclosed above that would have material financial impact or that required adjustment of the Company’s consolidated financial statements.

 

Park Ha Biological Technology Co., Ltd. (“Park Ha Cayman”) was incorporated in the Cayman Islands on October 11, 2022.

 

  F-35  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 22 — PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION

 

The condensed parent company financial statements have been prepared in accordance with Rule 12-04, Schedule I of Regulation S-X, as the restricted net assets of the subsidiaries of Park Ha Cayman exceed 25% of the consolidated net assets of the Company. For purposes of the test, restricted net assets of consolidated subsidiaries shall mean that amount of the registrant’s proportionate share of net assets of consolidated subsidiaries (after intercompany eliminations) which as of the end of the most recent fiscal year may not be transferred to the parent company by subsidiaries in the form of loans, advances or cash dividends without the consent of a third party (i.e., lender, regulatory agency, foreign government, etc.). The ability of the Company’s Chinese operating subsidiaries to pay dividends may be restricted due to the foreign exchange control policies and availability of cash balances of the Chinese operating subsidiaries. Because substantially all of the Company’s operations are conducted in China and a substantial majority of the Company’s revenues are generated in China, a majority of the Company’s revenue being earned and currency received are denominated in Renminbi (“RMB”). RMB is subject to the exchange control regulation in China, and, as a result, the Company may be unable to distribute any dividends outside of China due to PRC exchange control regulations that restrict the Company’s ability to convert RMB into US Dollars.

 

The condensed parent company financial statements have been prepared using the same accounting principles and policies described in the notes to the unaudited condensed consolidated financial statements, with the only exception being that the parent company accounts for its subsidiaries using the equity method. Refer to the unaudited condensed consolidated financial statements and notes presented above for additional information and disclosures with respect to these financial statements.

 

As of April 30, 2026 and October 31, 2025, there were no material contingencies, significant provisions of long-term obligations, mandatory dividend or redemption requirements of redeemable stock or guarantees of the Company, except for those that have been separately disclosed in the consolidated financial statements, if any.

 

Condensed Balance Sheets

 

    April 30,     October 31,  
    2026     2025  
ASSETS            
Current Assets                
Cash and cash equivalents     139,306       2,056,270  
Short Term Investment     3,805,278      
 
Other receivables and other current assets    
      293,333  
Total Current Assets     3,944,584       2,349,603  
Non-Current Assets    
 
     
 
 
Investment in subsidiaries and VIEs     3,483,557       3,716,103  
Total Non-Current Assets     3,483,557       3,716,103  
TOTAL ASSETS     7,428,141       6,065,706  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY                
Current Liabilities                
Accruals and other payables     30,000       60,000  
Intercompany Payable     2,010,851       2,010,851  
Total Current Liabilities     2,040,851       2,070,851  
TOTAL LIABILITIES     2,040,851       2,070,851  
Shareholders’ Equity                
Class A Ordinary Shares, $0.001 par value; 12,000,000,000 shares authorized;  4,543,884 and  296,488  shares issued and outstanding as of April 30,2026 and October 31, 2025, respectively;*     4,544       296  
Class B Ordinary Shares, $0.001 par value; 3,000,000,000 shares authorized; 381,000 shares issued and outstanding as of April 30,2026 and October 31, 2025, respectively*     381       381  
Additional Paid In Capital     30,261,334       28,021,581  
Statutory Reserve     217,264       217,264  
Accumulated Deficits     (25,096,549 )     (24,178,267 )
Accumulated Other Comprehensive income (Loss)     316       (66,400 )
Total Stockholders’ Equity     5,387,290       3,994,855  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY   7,428,141     6,065,706  

 

 

* Retroactively restated to reflect the share split, reverse share split and share reorganization (See Note 15)   

 

  F-36  

 

 

Park Ha Biological Technology Co., Ltd. and its Subsidiaries

Notes to the Unaudited Interim Condensed Consolidated Financial Statements

 

NOTE 22 — PARENT COMPANY ONLY CONDENSED FINANCIAL INFORMATION (cont.)

 

Condensed Statements of Operations

 

   

Six Months

Ended
April 30,

2026 

   

Six Months
Ended
April 30,

2025

 
Operating costs and expenses:            
General and administrative expenses     647,155       20,212,966  
Total operating expenses     647,155       20,212,966  
Other income (expense):    
     
 
Other income    
      29,001  
Interest income     28,140       196  
Interest (expense)     (4 )     (20 )
Total other income (expense), net     28,136       29,178  
Income (loss)  of subsidiaries and VIEs     (299,263 )     347,794  
Net loss     (918,282 )     (19,835,994 )

  

  F-37  

 

http://fasb.org/us-gaap/2026#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember P10Y http://fasb.org/srt/2026#ChiefOperatingOfficerMember 380000 0 0001986247 false 2026-04-30 Q2 --10-31 0001986247 2025-11-01 2026-04-30 0001986247 2026-04-30 0001986247 2025-10-31 0001986247 us-gaap:RelatedPartyMember 2026-04-30 0001986247 us-gaap:RelatedPartyMember 2025-10-31 0001986247 us-gaap:CommonClassAMember 2026-04-30 0001986247 us-gaap:CommonClassAMember 2025-10-31 0001986247 us-gaap:CommonClassBMember 2026-04-30 0001986247 us-gaap:CommonClassBMember 2025-10-31 0001986247 2024-11-01 2025-04-30 0001986247 us-gaap:CommonStockMember 2024-10-31 0001986247 us-gaap:AdditionalPaidInCapitalMember 2024-10-31 0001986247 phh:StatutoryReserveMember 2024-10-31 0001986247 us-gaap:RetainedEarningsMember 2024-10-31 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-31 0001986247 2024-10-31 0001986247 us-gaap:CommonStockMember 2024-11-01 2025-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2024-11-01 2025-04-30 0001986247 phh:StatutoryReserveMember 2024-11-01 2025-04-30 0001986247 us-gaap:RetainedEarningsMember 2024-11-01 2025-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-11-01 2025-04-30 0001986247 us-gaap:CommonStockMember 2025-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2025-04-30 0001986247 phh:StatutoryReserveMember 2025-04-30 0001986247 us-gaap:RetainedEarningsMember 2025-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-30 0001986247 2025-04-30 0001986247 us-gaap:CommonStockMember 2025-10-31 0001986247 us-gaap:AdditionalPaidInCapitalMember 2025-10-31 0001986247 phh:StatutoryReserveMember 2025-10-31 0001986247 us-gaap:RetainedEarningsMember 2025-10-31 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-10-31 0001986247 us-gaap:CommonStockMember 2025-11-01 2026-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2025-11-01 2026-04-30 0001986247 phh:StatutoryReserveMember 2025-11-01 2026-04-30 0001986247 us-gaap:RetainedEarningsMember 2025-11-01 2026-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-11-01 2026-04-30 0001986247 us-gaap:CommonStockMember 2026-04-30 0001986247 us-gaap:AdditionalPaidInCapitalMember 2026-04-30 0001986247 phh:StatutoryReserveMember 2026-04-30 0001986247 us-gaap:RetainedEarningsMember 2026-04-30 0001986247 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-30 0001986247 phh:XinZhanMember 2016-03-31 0001986247 phh:ParkHaJiangsuMember 2019-08-13 0001986247 phh:ParkHaBiologicalTechnologyHKCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:ParkHaInvestmentWuxiCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:JiangsuParkHaBiologicalTechnologyCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:WuxiXinzhanEnterpriseManagementConsultingCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:ShanghaiParkHaIndustrialDevelopmentCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:WuxiMuchenBiotechnologyCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:WuxiMufengBiotechnologyCoLtdMember 2025-11-01 2026-04-30 0001986247 phh:XinyuexuanBeautySalonWuxiEconomicDevelopmentZoneMember 2025-11-01 2026-04-30 0001986247 phh:AimeihuiBeautyCenterWuxiEconomicDevelopmentZoneMember 2025-11-01 2026-04-30 0001986247 phh:HuishanDistrictXuanyayueBeautySalonMember 2025-11-01 2026-04-30 0001986247 phh:HefengBeautvSalonMember 2025-11-01 2026-04-30 0001986247 phh:WuxiMaoheBiotechnologyCoLtdMember 2025-11-01 2026-04-30 0001986247 country:CN 2025-11-01 2026-04-30 0001986247 phh:PeriodEndMember 2026-04-30 0001986247 phh:PeriodEndMember 2025-10-31 0001986247 phh:AverageMember 2026-04-30 0001986247 phh:AverageMember 2025-04-30 0001986247 us-gaap:FurnitureAndFixturesMember 2026-04-30 0001986247 us-gaap:VehiclesMember 2026-04-30 0001986247 srt:MinimumMember us-gaap:OfficeEquipmentMember 2026-04-30 0001986247 us-gaap:LeaseholdImprovementsMember 2026-04-30 0001986247 srt:MaximumMember us-gaap:OfficeEquipmentMember 2026-04-30 0001986247 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-11-01 2026-04-30 0001986247 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2026-04-30 0001986247 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2025-10-31 0001986247 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2024-11-01 2025-04-30 0001986247 phh:TheParentCompanyParkHaCaymanMember us-gaap:VariableIncomeInterestRateMember 2025-11-01 2026-04-30 0001986247 phh:TheWFOEParkHaInvestmentMember us-gaap:VariableIncomeInterestRateMember 2025-11-01 2026-04-30 0001986247 phh:ThePrimaryBeneficiaryOfTheVIEsParkHaJiangsuMember us-gaap:VariableIncomeInterestRateMember 2025-11-01 2026-04-30 0001986247 phh:VIEsMember us-gaap:VariableIncomeInterestRateMember 2025-11-01 2026-04-30 0001986247 phh:OtherEntitiesMember us-gaap:VariableIncomeInterestRateMember 2025-11-01 2026-04-30 0001986247 phh:EliminationsMember us-gaap:VariableIncomeInterestRateMember 2025-11-01 2026-04-30 0001986247 phh:TheParentCompanyParkHaCaymanMember us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 phh:TheWFOEParkHaInvestmentMember us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 phh:ThePrimaryBeneficiaryOfTheVIEsParkHaJiangsuMember us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 phh:VIEsMember us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 phh:OtherEntitiesMember us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 phh:EliminationsMember us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 us-gaap:VariableIncomeInterestRateMember 2026-04-30 0001986247 phh:TheParentCompanyParkHaCaymanMember us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 phh:TheWFOEParkHaInvestmentMember us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 phh:ThePrimaryBeneficiaryOfTheVIEsParkHaJiangsuMember us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 phh:VIEsMember us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 phh:OtherEntitiesMember us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 phh:EliminationsMember us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 us-gaap:VariableIncomeInterestRateMember 2025-10-31 0001986247 phh:NonFranchiseesMember 2026-04-30 0001986247 phh:NonFranchiseesMember 2025-10-31 0001986247 phh:FranchiseesMember 2026-04-30 0001986247 phh:FranchiseesMember 2025-10-31 0001986247 phh:NonFranchiseesMember 2024-10-31 0001986247 phh:NonFranchiseesMember 2025-11-01 2026-04-30 0001986247 phh:NonFranchiseesMember 2024-11-01 2025-10-31 0001986247 phh:FranchiseesMember 2024-10-31 0001986247 phh:FranchiseesMember 2025-11-01 2026-04-30 0001986247 phh:FranchiseesMember 2024-11-01 2025-10-31 0001986247 us-gaap:FinancialAssetPastDueMember 2026-04-30 0001986247 us-gaap:FinancialAssetPastDueMember 2025-10-31 0001986247 us-gaap:FranchiseMember 2026-04-30 0001986247 us-gaap:LoansReceivableMember 2025-11-01 2026-04-30 0001986247 phh:GaoWenjingMember 2026-04-30 0001986247 phh:GaoWenjingMember 2025-10-31 0001986247 phh:WangShimeiMember 2026-04-30 0001986247 phh:WangShimeiMember 2025-10-31 0001986247 phh:ZengYongjianMember 2026-04-30 0001986247 phh:ZengYongjianMember 2025-10-31 0001986247 phh:SongMingfangMember 2026-04-30 0001986247 phh:SongMingfangMember 2025-10-31 0001986247 phh:WangZhiyaMember 2026-04-30 0001986247 phh:WangZhiyaMember 2025-10-31 0001986247 phh:YuYangMember 2026-04-30 0001986247 phh:YuYangMember 2025-10-31 0001986247 phh:YanTianxiangMember 2026-04-30 0001986247 phh:YanTianxiangMember 2025-10-31 0001986247 phh:WangXuefengMember 2026-04-30 0001986247 phh:WangXuefengMember 2025-10-31 0001986247 phh:ZhengYanhaiMember 2026-04-30 0001986247 phh:ZhengYanhaiMember 2025-10-31 0001986247 phh:ChenYuMember 2026-04-30 0001986247 phh:ChenYuMember 2025-10-31 0001986247 phh:ZhangYingMember 2026-04-30 0001986247 phh:ZhangYingMember 2025-10-31 0001986247 phh:WangHongliMember 2026-04-30 0001986247 phh:WangHongliMember 2025-10-31 0001986247 phh:GeXiaoqingMember 2026-04-30 0001986247 phh:GeXiaoqingMember 2025-10-31 0001986247 phh:ShengXidongMember 2026-04-30 0001986247 phh:ShengXidongMember 2025-10-31 0001986247 phh:ZhouGuixiangMember 2026-04-30 0001986247 phh:ZhouGuixiangMember 2025-10-31 0001986247 phh:WangJiaMember 2026-04-30 0001986247 phh:WangJiaMember 2025-10-31 0001986247 phh:MengHaoMember 2026-04-30 0001986247 phh:MengHaoMember 2025-10-31 0001986247 phh:SunZhongyaoMember 2026-04-30 0001986247 phh:SunZhongyaoMember 2025-10-31 0001986247 phh:WuYinghanMember 2026-04-30 0001986247 phh:WuYinghanMember 2025-10-31 0001986247 phh:LiuYupingMember 2026-04-30 0001986247 phh:LiuYupingMember 2025-10-31 0001986247 phh:XiaoYangMember 2026-04-30 0001986247 phh:XiaoYangMember 2025-10-31 0001986247 phh:ShenYueMember 2026-04-30 0001986247 phh:ShenYueMember 2025-10-31 0001986247 phh:ZhaoZheMember 2026-04-30 0001986247 phh:ZhaoZheMember 2025-10-31 0001986247 phh:ShenHuaimeiMember 2026-04-30 0001986247 phh:ShenHuaimeiMember 2025-10-31 0001986247 phh:SunXuqiangMember 2026-04-30 0001986247 phh:SunXuqiangMember 2025-10-31 0001986247 phh:ZhuHongjunMember 2026-04-30 0001986247 phh:ZhuHongjunMember 2025-10-31 0001986247 phh:WangJingfengMember 2026-04-30 0001986247 phh:WangJingfengMember 2025-10-31 0001986247 phh:TangSumeiMember 2026-04-30 0001986247 phh:TangSumeiMember 2025-10-31 0001986247 phh:LiRuonanMember 2026-04-30 0001986247 phh:LiRuonanMember 2025-10-31 0001986247 2024-11-01 2025-10-31 0001986247 us-gaap:FurnitureAndFixturesMember 2025-10-31 0001986247 us-gaap:VehiclesMember 2025-10-31 0001986247 us-gaap:OfficeEquipmentMember 2026-04-30 0001986247 us-gaap:OfficeEquipmentMember 2025-10-31 0001986247 us-gaap:LeaseholdImprovementsMember 2025-10-31 0001986247 us-gaap:TrademarksMember 2025-04-30 0001986247 us-gaap:TrademarksMember 2025-10-31 0001986247 us-gaap:SoftwareDevelopmentMember 2025-04-30 0001986247 us-gaap:SoftwareDevelopmentMember 2025-10-31 0001986247 2026-10-31 0001986247 phh:YanTianxiangMember 2026-04-30 0001986247 phh:YanTianxiangMember 2025-10-31 0001986247 phh:SongMingfangMember 2026-04-30 0001986247 phh:SongMingfangMember 2025-10-31 0001986247 phh:YuYangMember 2026-04-30 0001986247 phh:YuYangMember 2025-10-31 0001986247 phh:ShengXidongMember 2026-04-30 0001986247 phh:ShengXidongMember 2025-10-31 0001986247 phh:ZhouGuixiangMember 2026-04-30 0001986247 phh:ZhouGuixiangMember 2025-10-31 0001986247 phh:WangJiaMember 2026-04-30 0001986247 phh:WangJiaMember 2025-10-31 0001986247 phh:GeXiaoqingMember 2026-04-30 0001986247 phh:GeXiaoqingMember 2025-10-31 0001986247 phh:MengHaoMember 2026-04-30 0001986247 phh:MengHaoMember 2025-10-31 0001986247 phh:WangHongliMember 2026-04-30 0001986247 phh:WangHongliMember 2025-10-31 0001986247 phh:ZhangYingMember 2026-04-30 0001986247 phh:ZhangYingMember 2025-10-31 0001986247 phh:SunZhongyaoMember 2026-04-30 0001986247 phh:SunZhongyaoMember 2025-10-31 0001986247 phh:SunXuqiangMember 2026-04-30 0001986247 phh:SunXuqiangMember 2025-10-31 0001986247 phh:ZhengTinghaiMember 2026-04-30 0001986247 phh:ZhengTinghaiMember 2025-10-31 0001986247 phh:ZhuHongjunMember 2026-04-30 0001986247 phh:ZhuHongjunMember 2025-10-31 0001986247 phh:TangSumeiMember 2026-04-30 0001986247 phh:TangSumeiMember 2025-10-31 0001986247 phh:JinHuazhongMember 2026-04-30 0001986247 phh:JinHuazhongMember 2025-10-31 0001986247 phh:ShenHuaimeiMember 2026-04-30 0001986247 phh:ShenHuaimeiMember 2025-10-31 0001986247 phh:WangJingfengMember 2026-04-30 0001986247 phh:WangJingfengMember 2025-10-31 0001986247 phh:MsXiaoqiuZhangMember 2026-04-30 0001986247 phh:MsXiaoqiuZhangMember 2025-10-31 0001986247 phh:MsLiWangMember 2025-04-30 0001986247 phh:MsLiWangMember 2025-10-31 0001986247 phh:MsLiWangMember 2026-04-30 0001986247 phh:GuozhenLiuMember 2025-11-01 2026-04-30 0001986247 phh:FujunYuMember 2025-11-01 2026-04-30 0001986247 phh:HengquanZhangMember 2025-11-01 2026-04-30 0001986247 phh:XiaoqiuZhangMember 2025-11-01 2026-04-30 0001986247 phh:LiWangMember 2025-11-01 2026-04-30 0001986247 2021-11-01 2022-10-31 0001986247 2024-06-29 0001986247 us-gaap:IPOMember 2024-12-26 2024-12-26 0001986247 us-gaap:IPOMember 2024-12-26 0001986247 2024-12-26 2024-12-26 0001986247 us-gaap:OverAllotmentOptionMember 2025-01-24 2025-01-24 0001986247 us-gaap:OverAllotmentOptionMember 2025-01-24 0001986247 2025-01-24 2025-01-24 0001986247 phh:TwoThousandTwentyFiveEquityIncentivePlanMember us-gaap:CommonStockMember 2025-02-28 0001986247 phh:TwoThousandTwentyFiveEquityIncentivePlanMember 2025-02-28 0001986247 phh:FiveGrantAgreementsMember 2025-10-31 0001986247 phh:TwoThousandTwentyFiveEquityIncentivePlanMember 2025-07-07 0001986247 phh:FourGrantAgreementsMember 2024-11-01 2025-10-31 0001986247 phh:FourGrantAgreementsMember 2025-07-14 0001986247 phh:AssistantGeneralManagerMember 2025-10-03 0001986247 phh:AssistantGeneralManagerMember us-gaap:CommonClassAMember 2025-10-03 2025-10-03 0001986247 phh:AssistantGeneralManagerMember us-gaap:CommonClassAMember 2025-10-03 0001986247 phh:AssistantGeneralManagerMember us-gaap:CommonClassBMember 2025-10-03 0001986247 phh:AssistantGeneralManagerMember us-gaap:CommonClassBMember 2025-10-03 2025-10-03 0001986247 2025-12-26 2025-12-26 0001986247 phh:RoundingUpSharesMember 2026-02-20 2026-02-20 0001986247 phh:AdditionalAggregateSharesMember 2026-02-27 2026-02-27 0001986247 srt:MinimumMember us-gaap:CommonClassAMember 2026-02-27 0001986247 srt:MaximumMember us-gaap:CommonClassAMember 2026-02-27 0001986247 2026-01-28 2026-01-28 0001986247 2026-01-28 0001986247 us-gaap:CommonClassAMember 2026-01-28 0001986247 2026-02-20 2026-02-20 0001986247 us-gaap:CommonClassAMember 2026-02-20 2026-02-20 0001986247 us-gaap:WarrantMember 2026-01-27 0001986247 us-gaap:CommonClassAMember 2026-01-27 2026-01-27 0001986247 us-gaap:WarrantMember 2026-02-03 0001986247 us-gaap:CommonClassAMember 2026-02-03 2026-02-03 0001986247 us-gaap:WarrantMember 2026-02-04 0001986247 us-gaap:CommonClassAMember 2026-02-04 2026-02-04 0001986247 us-gaap:WarrantMember 2026-02-05 0001986247 us-gaap:CommonClassAMember 2026-02-05 2026-02-05 0001986247 us-gaap:WarrantMember 2026-02-23 0001986247 us-gaap:CommonClassAMember 2026-02-23 2026-02-23 0001986247 us-gaap:WarrantMember 2026-03-09 0001986247 us-gaap:CommonClassAMember 2026-03-09 2026-03-09 0001986247 us-gaap:WarrantMember 2026-04-21 0001986247 us-gaap:CommonClassAMember 2026-04-21 2026-04-21 0001986247 srt:ReportableGeographicalComponentsMember phh:ProductSalesMember 2025-11-01 2026-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:FranchiseFeesMember 2025-11-01 2026-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:ConsolidatedMember 2025-11-01 2026-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:ProductSalesMember 2024-11-01 2025-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:FranchiseFeesMember 2024-11-01 2025-04-30 0001986247 srt:ReportableGeographicalComponentsMember phh:ConsolidatedMember 2024-11-01 2025-04-30 0001986247 phh:ProductsSalesNonfranchiseesMember 2025-11-01 2026-04-30 0001986247 phh:ProductsSalesNonfranchiseesMember 2024-11-01 2025-04-30 0001986247 phh:ProductSalesFranchiseesMember 2025-11-01 2026-04-30 0001986247 phh:ProductSalesFranchiseesMember 2024-11-01 2025-04-30 0001986247 phh:FranchiseFeesMember 2025-11-01 2026-04-30 0001986247 phh:FranchiseFeesMember 2024-11-01 2025-04-30 0001986247 phh:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0001986247 phh:CustomerDMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001986247 phh:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0001986247 phh:CustomerJMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001986247 phh:CustomerLMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0001986247 phh:CustomerLMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001986247 phh:CustomerKMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-11-01 2026-04-30 0001986247 phh:CustomerKMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-11-01 2025-10-31 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierAMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierAMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierBMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierBMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierCMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierCMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierDMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierDMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierEMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierEMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierFMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierFMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierIMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierIMember 2024-11-01 2025-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierJMember 2025-11-01 2026-04-30 0001986247 phh:PurchasesMember us-gaap:SupplierConcentrationRiskMember phh:SupplierJMember 2024-11-01 2025-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierEMember 2025-11-01 2026-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierEMember 2024-11-01 2025-10-31 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierGMember 2025-11-01 2026-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierGMember 2024-11-01 2025-10-31 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierHMember 2025-11-01 2026-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierHMember 2024-11-01 2025-10-31 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierJMember 2025-11-01 2026-04-30 0001986247 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember phh:SupplierJMember 2024-11-01 2025-10-31 0001986247 country:HK 2025-11-01 2026-04-30 0001986247 phh:ParkHaBiologicalTechnologyMember 2025-11-01 2026-04-30 0001986247 phh:ChinaPRCMember phh:HighAndNewTechnologyEnterpriseMember 2026-04-30 0001986247 phh:HighAndNewTechnologyEnterpriseMember 2025-11-01 2026-04-30 0001986247 phh:ParkHaJiangsuMember 2025-11-01 2026-04-30 0001986247 srt:ScenarioForecastMember phh:SmallAndLowProfitEnterprisesSLPEsMember 2027-12-31 2027-12-31 0001986247 srt:ScenarioForecastMember 2027-12-31 2027-12-31 0001986247 srt:MinimumMember phh:CorporateIncomeTaxCITMember 2025-11-01 2026-04-30 0001986247 srt:MaximumMember phh:CorporateIncomeTaxCITMember 2025-11-01 2026-04-30 0001986247 phh:AiMeihuisAccountMember 2025-08-01 2025-12-31 0001986247 phh:AiMeihuisAccountMember 2026-04-30 0001986247 phh:AiMeihuisAccountMember 2025-07-01 2025-12-31 0001986247 phh:XinyuexuansAccountMember 2026-04-30 0001986247 srt:ScenarioForecastMember phh:XinyuexuansAccountMember 2026-01-01 2026-12-31 0001986247 srt:MinimumMember phh:TwoThousandTwentyFiveExtraordinaryGeneralMeetingMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-06-15 0001986247 srt:MinimumMember srt:ScenarioForecastMember phh:TwoThousandTwentyFiveExtraordinaryGeneralMeetingMember 2026-10-15 2026-10-15 0001986247 us-gaap:CommonClassBMember us-gaap:SubsequentEventMember 2026-10-15 0001986247 phh:PreFundedWarrantsMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-10-15 0001986247 phh:PreFundedWarrantsMember us-gaap:WarrantMember us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-10-15 0001986247 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-06-11 0001986247 us-gaap:SubsequentEventMember 2026-06-11 2026-06-11 0001986247 us-gaap:WarrantMember us-gaap:CommonClassAMember 2025-11-01 2026-04-30 0001986247 us-gaap:IPOMember 2025-11-01 2026-04-30 0001986247 us-gaap:SubsequentEventMember 2026-06-19 2026-06-19 0001986247 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-06-19 0001986247 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-06-19 2026-06-19 0001986247 us-gaap:SubsequentEventMember 2026-07-02 2026-07-02 0001986247 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2026-07-02 0001986247 us-gaap:CommonClassAMember us-gaap:SubsequentEventMember 2026-07-02 2026-07-02 0001986247 srt:ScenarioForecastMember us-gaap:CommonClassAMember 2026-07-13 0001986247 srt:MaximumMember srt:ScenarioForecastMember us-gaap:CommonClassBMember 2026-07-13 0001986247 srt:ScenarioForecastMember us-gaap:CommonClassBMember 2026-07-13 0001986247 srt:MaximumMember srt:ScenarioForecastMember us-gaap:CommonClassAMember 2026-07-13 2026-07-13 0001986247 srt:ScenarioForecastMember us-gaap:CommonClassAMember 2026-07-13 2026-07-13 0001986247 srt:MaximumMember srt:ScenarioForecastMember 2026-07-13 0001986247 srt:ScenarioForecastMember 2026-07-13 0001986247 srt:MinimumMember srt:ScenarioForecastMember 2026-07-13 0001986247 srt:ScenarioForecastMember us-gaap:CommonClassBMember 2026-07-13 2026-07-13 0001986247 phh:WuxiNinglanBiotechnologyCoLtdMember phh:JiangsuParkMember srt:ScenarioForecastMember 2026-05-29 2026-05-29 0001986247 phh:WuxiYoulanBiotechnologyCoLtdMember phh:JiangsuParkMember srt:ScenarioForecastMember 2026-05-29 2026-05-29 0001986247 phh:WuxiBoranBiotechnologyCoLtdMember phh:JiangsuParkMember srt:ScenarioForecastMember 2026-06-01 2026-06-01 0001986247 phh:WuxiManhuiBiotechnologyCoLtdMember phh:JiangsuParkMember srt:ScenarioForecastMember 2026-06-08 2026-06-08 0001986247 phh:WuxiAimeihuiBiotechnologyCoLtdMember phh:JiangsuParkMember srt:ScenarioForecastMember 2026-06-08 2026-06-08 0001986247 phh:WuxiHuiyanBiotechnologyCoLtdMember phh:JiangsuParkMember srt:ScenarioForecastMember 2026-07-15 2026-07-15 0001986247 srt:ParentCompanyMember 2026-04-30 0001986247 srt:ParentCompanyMember 2025-10-31 0001986247 srt:ParentCompanyMember us-gaap:CommonClassAMember 2026-04-30 0001986247 srt:ParentCompanyMember us-gaap:CommonClassAMember 2025-10-31 0001986247 srt:ParentCompanyMember us-gaap:CommonClassBMember 2026-04-30 0001986247 srt:ParentCompanyMember us-gaap:CommonClassBMember 2025-10-31 0001986247 srt:ParentCompanyMember 2025-11-01 2026-04-30 0001986247 srt:ParentCompanyMember 2024-11-01 2025-04-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure phh:Segment iso4217:HKD iso4217:CNY